<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Front Endocrinol (Lausanne)</journal-id><journal-id journal-id-type="iso-abbrev">Front Endocrinol (Lausanne)</journal-id><journal-id journal-id-type="publisher-id">Front. Endocrinol.</journal-id><journal-title-group><journal-title>Frontiers in Endocrinology</journal-title></journal-title-group><issn pub-type="epub">1664-2392</issn><publisher><publisher-name>Frontiers Media S.A.</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">29527188</article-id><article-id pub-id-type="pmc">5829030</article-id><article-id pub-id-type="doi">10.3389/fendo.2018.00049</article-id><article-categories><subj-group subj-group-type="heading"><subject>Endocrinology</subject><subj-group><subject>Original Research</subject></subj-group></subj-group></article-categories><title-group><article-title>Polysaccharide IV from <italic>Lycium barbarum L</italic>. Improves Lipid Profiles of Gestational Diabetes Mellitus of Pregnancy by Upregulating ABCA1 and Downregulating Sterol Regulatory Element-Binding Transcription 1 <italic>via</italic> miR-33</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Yang</surname><given-names>Shuli</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Si</surname><given-names>Lihui</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Fan</surname><given-names>Limei</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Jian</surname><given-names>Wenwen</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Pei</surname><given-names>Huilin</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Lin</surname><given-names>Ruixin</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="corresp" rid="cor1">*</xref><uri xlink:type="simple" xlink:href="http://frontiersin.org/people/u/494534"/></contrib></contrib-group><aff id="aff1"><sup>1</sup><institution>Department of Gynecology and Obstetrics, The Second Hospital of Jilin University</institution>, <addr-line>Changchun</addr-line>, <country>China</country></aff><aff id="aff2"><sup>2</sup><institution>Department of Hepatobiliary and Pancreatic Surgery, The Second Hospital of Jilin University</institution>, <addr-line>Changchun</addr-line>, <country>China</country></aff><author-notes><fn fn-type="edited-by"><p>Edited by: Oliana Carnevali, Universit&#x000e0; Politecnica delle Marche, Italy</p></fn><fn fn-type="edited-by"><p>Reviewed by: Yicong Li, Johns Hopkins Medicine, United States; Yung-Hsi Kao, National Central University, Taiwan</p></fn><corresp content-type="corresp" id="cor1">*Correspondence: Ruixin Lin, <email>linruix1027@163.com</email></corresp><fn fn-type="other" id="fn001"><p>Specialty section: This article was submitted to Experimental Endocrinology, a section of the journal Frontiers in Endocrinology</p></fn></author-notes><pub-date pub-type="epub"><day>23</day><month>2</month><year>2018</year></pub-date><pub-date pub-type="collection"><year>2018</year></pub-date><volume>9</volume><elocation-id>49</elocation-id><history><date date-type="received"><day>05</day><month>11</month><year>2017</year></date><date date-type="accepted"><day>05</day><month>2</month><year>2018</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2018 Yang, Si, Fan, Jian, Pei and Lin.</copyright-statement><copyright-year>2018</copyright-year><copyright-holder>Yang, Si, Fan, Jian, Pei and Lin</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p></license></permissions><abstract><p><italic>Lycium barbarum L</italic>. (LBL) has beneficial effects on gestational diabetes mellitus (GDM) but the related mechanism remains unclear. Polysaccharides of LBL (LBLP) are the main bioactive components of LBL. miR-33, ATP-binding cassette transporter A1 (ABCA1) and sterol regulatory element-binding transcription 1 (SREBF1) affect lipid profiles, which are associated with GDM risk. LBLP may exert protective against GDM by affecting these molecules. Four LBLP fractions: LBLP-I, LBLP-II, LBLP-III, and LBLP-IV were isolated from LBL and further purified by using DEAE-Sephadex column. The effects of purified each fraction on pancreatic beta cells were comparatively evaluated. A total of 158 GDM patients were recruited and randomly divided into LBL group (LG) and placebo group (CG). miR-33 levels, lipid profiles, insulin resistance and secretory functions were measured. The association between serum miR-33 levels and lipid profiles were evaluated by using Spearman&#x02019;s rank-order correlation test. After 4-week therapy, LBL reduced miR-33 level, insulin resistance and increased insulin secretion of GDM patients. LBL increased the levels of ABCA1, high-density lipoprotein cholesterol (HDL-C) and reduced miR-33, SREBF1, low-density lipoprotein cholesterol (LDL-C), total cholesterol (TC), triglyceride (TG), and malondialdehyde. Homeostatic model assessment of &#x003b2;-cell function and insulin resistance was lower in LG than in CG, whereas homeostatic model assessment of &#x003b2;-cell function and insulin secretory function was higher in LG than in CG. There was a strong positive association between miR-33 level and TG, or TC and or LDL-C, and a strong negative association between miR-33 level and HDL-C. The levels of miR-33 had negative relation with ABCA1 and positive relation with SREBF1. ABCA1 has negative relation with TG, TC, and LDL-C and positive relation with HDL-C. Inversely, SREBF1 had positive relation with TG, TC, and LDL-C and negative relation with HDL-C. The main bioactive compound LBLP-IV of LBL increased insulin secretion of beta cells and the levels of ABCA1, and reduced miR-33 levels and SREBF1 in beta cells. However, LBLP-IV could not change the levels of these molecules anymore when miR-33 was overexpressed or silenced. LBLP-IV had the similar effects with LBL on beta cells while other components had no such effects. Thus, LBLP-IV from LBL improves lipid profiles by upregulating ABCA1 and downregulating SREBF1 <italic>via</italic> miR-33.</p></abstract><kwd-group><kwd><italic>Lycium barbarum L.</italic></kwd><kwd>gestational diabetes mellitus</kwd><kwd>ATP-binding cassette transporter A1</kwd><kwd>sterol regulatory element-binding transcription</kwd><kwd>miR-33</kwd></kwd-group><counts><fig-count count="7"/><table-count count="3"/><equation-count count="0"/><ref-count count="77"/><page-count count="13"/><word-count count="8772"/></counts></article-meta></front><body><sec sec-type="introduction" id="S1"><title>Introduction</title><p>Gestational diabetes mellitus (GDM), a special type of diabetes, is caused by multiple factors with genetic predisposition (<xref rid="B1" ref-type="bibr">1</xref>) and endocrine metabolic diseases (<xref rid="B2" ref-type="bibr">2</xref>, <xref rid="B3" ref-type="bibr">3</xref>). GDM is defined as the different glucose intolerance that occurs within the first trimester of pregnancy. It is estimated that the incidence of GDM represents average 3&#x02013;8% of all pregnancies (<xref rid="B4" ref-type="bibr">4</xref>). GDM incidence will continue to increase due to the changes of lifestyle and living conditions. Compared with other types of diabetes mellitus, GDM not only affects their own health status and but also increases the risk of postpartum diabetes. Previous study showed that the cumulative incidence of type 2 diabetes mellitus was 6&#x02009;weeks to 28&#x02009;years in postpartum women with GDM (<xref rid="B5" ref-type="bibr">5</xref>). GDM has negative effects on future generations, including neonatal death (<xref rid="B6" ref-type="bibr">6</xref>), stillbirth (<xref rid="B7" ref-type="bibr">7</xref>), perinatal mortality (<xref rid="B8" ref-type="bibr">8</xref>), preeclampsia (<xref rid="B9" ref-type="bibr">9</xref>), large fetus (<xref rid="B10" ref-type="bibr">10</xref>), neonatal jaundice (<xref rid="B11" ref-type="bibr">11</xref>), low blood sugar (<xref rid="B12" ref-type="bibr">12</xref>), low calcium (<xref rid="B13" ref-type="bibr">13</xref>), and so on. However, the pathogenesis of GDM is still not fully understood. Many countries have invested much money on the research programs of GDM, including GDM pathogenesis, impact factors and diagnostic criteria. Living environment (<xref rid="B14" ref-type="bibr">14</xref>), family history (<xref rid="B15" ref-type="bibr">15</xref>), pregnancy (<xref rid="B16" ref-type="bibr">16</xref>, <xref rid="B17" ref-type="bibr">17</xref>), low birth weight (<xref rid="B18" ref-type="bibr">18</xref>), prepregnancy obesity (<xref rid="B19" ref-type="bibr">19</xref>), and dietary imbalance (<xref rid="B20" ref-type="bibr">20</xref>, <xref rid="B21" ref-type="bibr">21</xref>) are common risk factors of GDM. Balanced nutrition and appropriate physical labor and exercise are the main methods for preventing the occurrence of GDM (<xref rid="B22" ref-type="bibr">22</xref>).</p><p>Medical treatment is still the main method for GDM therapy (<xref rid="B23" ref-type="bibr">23</xref>, <xref rid="B24" ref-type="bibr">24</xref>). However, the safety or efficacy of the medicine remains unclear in pregnancy (<xref rid="B25" ref-type="bibr">25</xref>, <xref rid="B26" ref-type="bibr">26</xref>). It is necessary to find natural medicine with a fewer side effects. <italic>Lycium barbarum L</italic>. (LBL) is a deciduous woody perennial plant primarily in the Ningxia Hui Autonomous Region (Ningxia, China) (<xref rid="B27" ref-type="bibr">27</xref>). Polysaccharides of LBL (LBLP) are the main bioactive components (<xref rid="B28" ref-type="bibr">28</xref>, <xref rid="B29" ref-type="bibr">29</xref>). LBLP-IV administration has been reported to control the animal model with diabetes. LBLP-IV may be a potential therapeutic agent in diabetic treatment (<xref rid="B30" ref-type="bibr">30</xref>). However, the molecular mechanism for the effects of LBLP-IV on diabetes remains unknown. MicroRNA is short, single-stranded RNA molecules with 22 nucleotides in length. MiR-33 can regulate lipid metabolism (<xref rid="B31" ref-type="bibr">31</xref>), which is associated with GDM. There is much evidence linking miR-33 to lipid metabolism by targeting ATP-binding cassette transporter A1 (ABCA1) and sterol regulatory element-binding transcription 1 (SREBF1) (<xref rid="B32" ref-type="bibr">32</xref>). ABCA1 is the cholesterol efflux regulatory protein, which regulates cholesterol efflux and phospholipid homeostasis (<xref rid="B33" ref-type="bibr">33</xref>). SREBP are the transcription factors, which bind to the sterol regulatory element and repressed its expression, including ABCA1 gene (<xref rid="B34" ref-type="bibr">34</xref>). ABCA1 (<xref rid="B35" ref-type="bibr">35</xref>) and SREBF1 (<xref rid="B36" ref-type="bibr">36</xref>) affect lipid metabolism too. Thus, the polysaccharides may improve lipid profiles by affecting ABCA1 and SREBF1 levels <italic>via</italic> miR-33. However, the miR-33-related molecular mechanisms for the functions of LBL on GDM patients are still unclear.</p><p>In this study, we want to explore the effects of LBL on GDM patients by investigating serum lipid profiles and related molecules. Changes in the miR-33, ABCA-1, and SREBF1 expressions, as well as insulin sensitivity and blood insulin and resistin levels, were also assessed. Meanwhile, the bioactive compound from LBL was isolated and its effects on &#x003b2; cell were measured.</p></sec><sec sec-type="materials|methods" id="S2"><title>Materials and Methods</title><sec id="S2-1"><title>LBL Polysaccharides Isolation</title><p><italic>Lycium barbarum L</italic>. leaves were purchased from Ningxia, China and LBL polysaccharides were isolated according to an early report (<xref rid="B37" ref-type="bibr">37</xref>). Fifty-microgram LBL leaves were crushed to fine powder and extracted in triplicate by using 1&#x02009;l distilled water for 1&#x02009;h at 90&#x000b0;C. The filtrated solution was concentrated by using a rotary evaporator (RE-52A, Shanghai Woshi Co., Shanghai, China) at 55&#x000b0;C, and precipitated by adding fourfold volume of anhydrous ethanol. LBLP were washed three times with anhydrous ethanol and acetone after being centrifuged at 3,000&#x02009;rpm for 15&#x02009;min, and then and finally lyophilized. The crude protein was removed by using the Sevag method (<xref rid="B38" ref-type="bibr">38</xref>) and decolorized with the macroreticular resin AB-8 (Cangzhou Resin Company, Cangzhou, Hebei, China). Final polysaccharides were isolated by using a DEAE SephadexA-25 column (Amersham Pharmacia Biotech, Piscataway, NJ, USA) equilibrated with distilled water for one day. Individual polysaccharide was eluted with distilled water, 0.1 and 0.2&#x02009;M NaCl at 0.8&#x02009;mL/min. The polysaccharide fractions were collected at 2&#x02009;min/tube using an automatic collector (Beijing Xinhuizeao Technology Co., Ltd., Beijing, China), then the collected solution was dialyzed (MWCO 3600, Sigma) and lyophilized finally.</p><p>The homogeneity of isolated polysaccharide was determined by high-performance gel-permeation chromatography (HP-GPC) (Dionex, Sunnyvale, CA, USA). Twenty-microliter sample solution was performed at a flow rate of 0.5&#x02009;mL/min (distilled water and 100, 200&#x02009;mM NaCl) as a mobile phase. The columns were calibrated with T-series dextran (T-10, 40, 70, 500, 2,000), and the molecular weight of polysaccharides was confirmed by referencing to a calibrated curve.</p></sec><sec id="S2-2"><title>Participants</title><p>All protocols were approved by ethical committee of our hospital (Approval no. 201602X4), and the study was carried out according to the principles described in the World Medical Association Declaration of Helsinki (<xref rid="B39" ref-type="bibr">39</xref>). All subjects gave written informed consent in accordance with the Declaration of Helsinki. From April 2016 to May 2016, a total of 158 women diagnosed with GDM were collected at our hospital. All the pregnant women met the diagnostic criteria of GDM <italic>via</italic> a 2-h 75-g oral glucose tolerance test according to an earlier report (<xref rid="B40" ref-type="bibr">40</xref>).</p></sec><sec id="S2-3"><title>Including Criteria</title><p>Pregnant women were age 18&#x02013;40&#x02009;years; the patient had singleton pregnancy and no previous GDM; pregnant women had an impairment of their glucose tolerance according to the results of a 2-h 75-g oral glucose tolerance test; the patients were diagnosed with GDM from 26 to 30&#x02009;weeks of gestation.</p></sec><sec id="S2-4"><title>Excluding Criteria</title><p>The patients were smokers and or alcohol drinkers; some condition and or medication that affected glucose levels; the patients were unwilling to follow the prescribed diet. The patients had cardiac, dizziness, and related diseases; the patients had obvious abnormal clinical findings.</p></sec><sec id="S2-5"><title>GDM Patients Grouping</title><p>After screening <italic>via</italic> inclusion and exclusion criteria, 158 patients were evenly and randomly assigned into a LBL group (LG, received 10-mg LBL daily) and a control group (CG, received 10-mg placebo daily) (Figure <xref ref-type="fig" rid="F1">1</xref>).</p><fig id="F1" position="float"><label>Figure 1</label><caption><p>Flowchart of the study population. ABCA1, ATP-binding cassette transporter A1. SREBF1, sterol regulatory element-binding transcription. The whole period was 4&#x02009;weeks.</p></caption><graphic xlink:href="fendo-09-00049-g001"/></fig></sec><sec id="S2-6"><title>Blood Glucose (BG) Measurement</title><p>Five-milliliter blood is either directly sucked into a vacuum test tube from a vein of each patients. Serum was isolated by centrifugation at 10,000&#x02009;rpm for 5&#x02009;min. The concentration of BG was measured by using glucose oxidase (<xref rid="B41" ref-type="bibr">41</xref>). Unified quality control standards were used for all the 26&#x02013;30-week pregnancy with GDM. Fasting blood glucose (FBG) was measured in the morning <italic>via</italic> centrifugation after taking venous blood from each subject, and then dissolved in two pairs of bottles filled with water.</p></sec><sec id="S2-7"><title>Biochemical Analysis</title><p>The concentrations of glucose and HbAlc were measured after taking 2-h 75&#x02009;g oral glucose. The concentration of BG was measured by using glucose oxidase (<xref rid="B41" ref-type="bibr">41</xref>). Serum HbA1c levels were measured by was measured by HPLC (D-10 Dual Program; Bio-Rad, Hercules, CA, USA). High- and low-density lipoprotein-cholesterol (HDL-C and LDL-C) were measured by using an Olympus AU 600 auto-analyzer (Olympus Optical Co. Ltd., Schimatsu-Mishima, Japan). Triglyceride (TG) levels were measured a Technicon RA-500 analyzer (Bayer, Etobicoke, ON, Canada). Basal BG and FBG levels were examined by ABL 800FLEX blood gas analyzer (Midland, ON, Canada). Serum resistin was measured by using the resistin ELISA kit from Phoenix Pharmaceuticals (Belmont, CA, USA) according to manufacturer&#x02019;s instructions. Serum basal insulin and fasting insulin (FINS) were tested by radioimmunoassay (Linco, Seaford, DE, USA). Homeostatic model assessment of &#x003b2;-cell function and insulin resistance (HOMA-IR) and homeostatic model assessment of &#x003b2;-cell function and insulin secretory function (HOMA-IS) were measured by using the following equations: HOMA-IR&#x02009;=&#x02009;FBG&#x02009;&#x000d7;&#x02009;FINS/22.5 and HOMA-IS&#x02009;=&#x02009;20&#x02009;&#x000d7;&#x02009;FINS/(FBG&#x02009;&#x02212;&#x02009;3.5), respectively.</p></sec><sec id="S2-8"><title>Measurement of Serum Lipid Profiles</title><p>Two-milliliter serum was separated from whole blood by allowing the blood to just let stand. A lipid profiles is closely associated with the risk of GDM (<xref rid="B42" ref-type="bibr">42</xref>&#x02013;<xref rid="B44" ref-type="bibr">44</xref>). Lipid profiles were measured by using the same method in Section &#x0201c;<xref ref-type="sec" rid="S2-10">MiR-33 Silencing</xref>.&#x0201d; Malondialdehyde (MDA) level was measured by using a MDA detection kit (A003; Nanjing Jiancheng Bioengineering Institute, Nanjing, China). Lipid indexes were measured before and after 4-week experiment.</p></sec><sec id="S2-9"><title>Cell Culture</title><p>Gestational diabetes mellitus represents the major diabetes, and &#x003b2;-cell dysfunction plays an important role in the development and progression of the disease. The components purified by DEAE-Sephadex A-25 column, were measured by using human pancreatic carcinoma cell SW1990, which was purchased from cell bank, CAS (Shanghai, China). The cell lines were cultured in RPMI-1640 at 37&#x000b0;C with 5% CO<sub>2</sub>. After 3-day culture, the cell concentrations were adjusted to 1&#x02009;&#x000d7;&#x02009;10<sup>5</sup>&#x02009;cells/mL and 100&#x02009;&#x000b5;L cells were transferred to each cell of 96-cell plate, treated with 10&#x02009;&#x000b5;g/mL different fractions and further cultured for three days under the same situation.</p></sec><sec id="S2-10"><title>MiR-33 Silencing</title><p>Lipofectamine&#x02122; 2000 (Invitrogen, Waltham, MA, USA) was used to transfect islet &#x003b2;-cell line SW1990 with miR-33 RISC complex. 10<sup>5</sup> SW1990 cells were seeded in six-well plates. Scrambled control siRNA was carried out (Beijing Dingguo Changsheng Biotechnology, Beijing, China). miR-33 (GenBank No., NR_029507.1) four target siRNA sequences: UGUGGUGCAUUGUAGUUGCAUUGCA, UGGUGCAUUGUAGUUGCAUUGCAUG, GCAUUGUAGUUGCAUUGCAUGUUCU and CAUUGUAGUUGCAUUGCAUGUUCUG. The transfection with 40&#x02009;nM siRNA was performed in DMEM (with 1% <sc>l</sc>-glutamine, 10% FCS and without penicillin/streptomycin) for 72&#x02009;h.</p></sec><sec id="S2-11"><title>The Effects of LBL Fractions on Insulin Secretion in SW1990 Cells</title><p>SW1990 were seeded in 24-well plates (1&#x02009;&#x000d7;&#x02009;10<sup>5</sup>&#x02009;cells/well), treated with different fractions of LBL and cultured for 3&#x02009;days to investigate insulin secretion. Insulin level was measured by using an insulin ELISA kit (Thermo Fisher Scientific Inc., Cleveland, OH, USA). After the determination of bioactive components, LBL was then used for clinical trials.</p></sec><sec id="S2-12"><title>Quantitative RT-PCR Analysis</title><p>Blood samples were obtained from GDM patients. Serum was isolated from blood samples within 2&#x02009;h. Total RNA was extracted by using a miRNeasy Serum/Plasma Kit (QIAGEN Sciences, Germantown, MD, USA). Finally, 2-&#x000b5;g RNA was obtained from 1-mL serum. MiR-33 (GenBank No. NR_029507.1), forward primer: 5&#x02032;-GTCCGTGGTGCATTGTAGT-3&#x02032;; reverse primer: 5&#x02032;-GTGCAGGGTCCGAGGT-3&#x02032;. U6 (GenBank No. NR_004394.1), forward primer: 5&#x02032;-TTGGTGCTCGCTTCGGCA-3&#x02032;; reverse primer: 5&#x02032;-GTGCAGGGTCCGAGGT-3&#x02032;. U6 snRNA was used as an internal control. ABCA1 (GenBank No. AB055982.1), forward primer: 5&#x02032;-ATTGTGGCTCGCCTGTTCTC-3&#x02032;; reverse primer: 5&#x02032;-TAGACTTTGGGAGAGAGAGG-3&#x02032;. SREBF1 (GenBank No. NM_001005291.2), forward primer: 5&#x02032;-TGAGCTCCTCTCTTGAAGCC-3&#x02032;; reverse primer: 5&#x02032;-GTAGCCTAACACAGGGGTGG-3&#x02032;; Beta actin (GeanBank No. HQ154074.1, as a loading control), forward primer: 5&#x02032;-TCCAGCCTTCCTTCCTGGGC-3&#x02032;; reverse primer: 5&#x02032;-GCCAGGGTACATGGTGGTAC-3&#x02032;. qRT-PCR was conducted by using an Applied Biosystems 7300 Real-time PCR System. 1-&#x000b5;L RT products were added to 20-&#x000b5;L reaction volume including 0.5-&#x000b5;L sense primer and reverse primer, 1-&#x000b5;L SYBR<sup>&#x000ae;</sup> Green Real-Time PCR Master Mixes (Thermo Fisher Scientific, Waltham, MA, USA), and one-unit Taq [Takara Biotechnology (Dalian) Co., Ltd., Dalian, China]. The reaction was carried out by using the following parameters: 94&#x000b0;C for 5&#x02009;min, followed by 45 cycles of 94&#x000b0;C for 20&#x02009;s and 65&#x000b0;C for 1&#x02009;min. After the reaction, the CT was calculated <italic>via</italic> threshold settings. The ratio of uterine sarcoma serum miRNA and healthy subjects was presented by using 2&#x02009;<sup>&#x02212;&#x02009;&#x00394;G</sup>, in which &#x00394;G&#x02009;=&#x02009;C<sub>T cancer</sub>&#x02009;&#x02212;&#x02009;C<sub>T normal</sub>.</p></sec><sec id="S2-13"><title>Western Blot Analysis</title><p>SW1990 cell lines were treated with cocktail and lysed <italic>via</italic> a freezing and thawing method. Meanwhile, serum samples were also prepared for Western Blot analysis. Twenty-five microgram proteins were separated by 12% SDS-PAGE and transferred to a PVDF membrane, which was blocked by non-fat milk for 30&#x02009;min. The membranes were incubated with the antibodies ABCA1 (ab66217) and SREBF1 (ab28481), Beta actin (ab6276, as a loading control), goat polyclonal secondary antibody to rabbit IgG-H&#x00026;L (HRP) (ab6721, Abcam, Cambridge, MA, USA). With X-ray film exposure, the expression of ABCA1 and SREBF1 was detected <italic>via</italic> Quantity One software.</p></sec><sec id="S2-14"><title>Statistical Analysis</title><p>Results were presented as the mean&#x02009;&#x000b1;&#x02009;SEM. Paired student&#x02019;s <italic>t</italic>-test was used to compare the differences between two groups. Spearman&#x02019;s rank-order correlation test was used to test the relationship between two variables. There were statistically significant differences if <italic>P</italic>&#x02009;&#x0003c;&#x02009;0.05.</p></sec></sec><sec id="S3"><title>Results</title><sec id="S3-1"><title>Characterization of LBL</title><p>Four main polysaccharides were isolated from LBL after the purification of DEAE-Sephadex A-25 column (Figure <xref ref-type="fig" rid="F2">2</xref>A), which was accordant with an earlier report (<xref rid="B37" ref-type="bibr">37</xref>). The isolated components were further confirmed by HP-GPC under the conditions that produced masses predicted for LBLP I (Figure <xref ref-type="fig" rid="F2">2</xref>B), LBLP II (Figure <xref ref-type="fig" rid="F2">2</xref>C), LBLP III (Figure <xref ref-type="fig" rid="F2">2</xref>D), and LBLP IV (Figure <xref ref-type="fig" rid="F2">2</xref>E) were 55.2, 94.0, 241.3, and 418.0&#x02009;kDa, respectively.</p><fig id="F2" position="float"><label>Figure 2</label><caption><p>The polysaccharides of the extracts of <italic>Lycium barbarum L</italic>. (LBL) are purified by using a DEAE SephadexA-25 column. <bold>(A)</bold> There are four main polysaccharides [polysaccharides of LBL (LBLP) I, II, III, and IV] in the extracts of LBL <bold>(B)</bold> High-performance gel-permeation chromatography (HP-GPC) analysis of LBLP I. <bold>(C)</bold> HP-GPC analysis of LBLP II. <bold>(D)</bold> HP-GPC analysis of LBLP III. <bold>(E)</bold> HP-GPC analysis of LBLP IV.</p></caption><graphic xlink:href="fendo-09-00049-g002"/></fig></sec><sec id="S3-2"><title>Baseline Characters</title><p>Table <xref ref-type="table" rid="T1">1</xref> shows the clinical characters were similar between two groups. The mean ages of were at age of 30.1&#x02009;&#x000b1;&#x02009;5.4 in LG and 29.5&#x02009;&#x000b1;&#x02009;4.3 in CG. The statistical difference was insignificant for baseline demographic and metabolic characteristics of the patients between two groups (<italic>P</italic>&#x02009;&#x0003e;&#x02009;0.05).</p><table-wrap id="T1" position="float"><label>Table 1</label><caption><p>Baseline demographic and metabolic characteristics of GDM (gestational diabetes mellitus of pregnancy) subjects.</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top" align="left" rowspan="1" colspan="1">Characteristics of patients</th><th valign="top" align="center" rowspan="1" colspan="1">LG (<italic>n</italic>&#x02009;=&#x02009;79)</th><th valign="top" align="center" rowspan="1" colspan="1">CG (<italic>n</italic>&#x02009;=&#x02009;79)</th><th valign="top" align="center" rowspan="1" colspan="1"><italic>t</italic>/&#x003c7;<sup>2</sup></th><th valign="top" align="center" rowspan="1" colspan="1"><italic>P</italic>-value</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">Age (years)</td><td align="center" valign="top" rowspan="1" colspan="1">30.1&#x02009;&#x000b1;&#x02009;5.4</td><td align="center" valign="top" rowspan="1" colspan="1">29.5&#x02009;&#x000b1;&#x02009;4.3</td><td align="center" valign="top" rowspan="1" colspan="1">0.23</td><td align="center" valign="top" rowspan="1" colspan="1">0.64<xref ref-type="table-fn" rid="tfn1"><sup>a</sup></xref></td></tr><tr><td align="left" valign="top" colspan="5" rowspan="1">Race, <italic>n</italic> (%)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Han Zhu</td><td align="center" valign="top" rowspan="1" colspan="1">64</td><td align="center" valign="top" rowspan="1" colspan="1">65</td><td align="center" valign="top" rowspan="1" colspan="1">0.04</td><td align="center" valign="top" rowspan="1" colspan="1">0.84<xref ref-type="table-fn" rid="tfn2"><sup>b</sup></xref></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Manchu</td><td align="center" valign="top" rowspan="1" colspan="1">10</td><td align="center" valign="top" rowspan="1" colspan="1">9</td><td align="center" valign="top" rowspan="1" colspan="1">0.06</td><td align="center" valign="top" rowspan="1" colspan="1">0.81<xref ref-type="table-fn" rid="tfn2"><sup>b</sup></xref></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Mongolians</td><td align="center" valign="top" rowspan="1" colspan="1">4</td><td align="center" valign="top" rowspan="1" colspan="1">4</td><td align="center" valign="top" rowspan="1" colspan="1">0.13</td><td align="center" valign="top" rowspan="1" colspan="1">0.72<xref ref-type="table-fn" rid="tfn2"><sup>b</sup></xref></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Tibetans</td><td align="center" valign="top" rowspan="1" colspan="1">1</td><td align="center" valign="top" rowspan="1" colspan="1">1</td><td align="center" valign="top" rowspan="1" colspan="1">0.51</td><td align="center" valign="top" rowspan="1" colspan="1">0.48<xref ref-type="table-fn" rid="tfn2"><sup>b</sup></xref></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Body weight (kg)</td><td align="center" valign="top" rowspan="1" colspan="1">68.3&#x02009;&#x000b1;&#x02009;10.2</td><td align="center" valign="top" rowspan="1" colspan="1">67.9&#x02009;&#x000b1;&#x02009;11.5</td><td align="center" valign="top" rowspan="1" colspan="1">0.97</td><td align="center" valign="top" rowspan="1" colspan="1">0.12<xref ref-type="table-fn" rid="tfn1"><sup>a</sup></xref></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">BMI (kg/m<sup>2</sup>)</td><td align="center" valign="top" rowspan="1" colspan="1">28.4&#x02009;&#x000b1;&#x02009;4.9</td><td align="center" valign="top" rowspan="1" colspan="1">27.7&#x02009;&#x000b1;&#x02009;5.3</td><td align="center" valign="top" rowspan="1" colspan="1">0.86</td><td align="center" valign="top" rowspan="1" colspan="1">0.25<xref ref-type="table-fn" rid="tfn1"><sup>a</sup></xref></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Insulin (mIU/L)</td><td align="center" valign="top" rowspan="1" colspan="1">20.6&#x02009;&#x000b1;&#x02009;2.3</td><td align="center" valign="top" rowspan="1" colspan="1">20.5&#x02009;&#x000b1;&#x02009;2.6</td><td align="center" valign="top" rowspan="1" colspan="1">0.23</td><td align="center" valign="top" rowspan="1" colspan="1">0.69<xref ref-type="table-fn" rid="tfn1"><sup>a</sup></xref></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">HbA1c (%)</td><td align="center" valign="top" rowspan="1" colspan="1">6.9&#x02009;&#x000b1;&#x02009;1.7</td><td align="center" valign="top" rowspan="1" colspan="1">6.7&#x02009;&#x000b1;&#x02009;1.9</td><td align="center" valign="top" rowspan="1" colspan="1">0.72</td><td align="center" valign="top" rowspan="1" colspan="1">0.58<xref ref-type="table-fn" rid="tfn1"><sup>a</sup></xref></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">FBG (mmol/L)</td><td align="center" valign="top" rowspan="1" colspan="1">8.3&#x02009;&#x000b1;&#x02009;1.1</td><td align="center" valign="top" rowspan="1" colspan="1">8.4&#x02009;&#x000b1;&#x02009;1.2</td><td align="center" valign="top" rowspan="1" colspan="1">0.84</td><td align="center" valign="top" rowspan="1" colspan="1">0.32<xref ref-type="table-fn" rid="tfn1"><sup>a</sup></xref></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">2hPG (mmol/L)</td><td align="center" valign="top" rowspan="1" colspan="1">14.9&#x02009;&#x000b1;&#x02009;2.5</td><td align="center" valign="top" rowspan="1" colspan="1">14.1&#x02009;&#x000b1;&#x02009;3.2</td><td align="center" valign="top" rowspan="1" colspan="1">0.60</td><td align="center" valign="top" rowspan="1" colspan="1">0.55<xref ref-type="table-fn" rid="tfn1"><sup>a</sup></xref></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">TG (mmol/L)</td><td align="center" valign="top" rowspan="1" colspan="1">2.8&#x02009;&#x000b1;&#x02009;1.2</td><td align="center" valign="top" rowspan="1" colspan="1">2.7&#x02009;&#x000b1;&#x02009;1.4</td><td align="center" valign="top" rowspan="1" colspan="1">0.19</td><td align="center" valign="top" rowspan="1" colspan="1">0.81<xref ref-type="table-fn" rid="tfn1"><sup>a</sup></xref></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">TC (mmol/L)</td><td align="center" valign="top" rowspan="1" colspan="1">5.9&#x02009;&#x000b1;&#x02009;1.4</td><td align="center" valign="top" rowspan="1" colspan="1">5.7&#x02009;&#x000b1;&#x02009;1.6</td><td align="center" valign="top" rowspan="1" colspan="1">0.24</td><td align="center" valign="top" rowspan="1" colspan="1">0.40<xref ref-type="table-fn" rid="tfn1"><sup>a</sup></xref></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">HDL-C (mmol/L)</td><td align="center" valign="top" rowspan="1" colspan="1">1.3&#x02009;&#x000b1;&#x02009;0.3</td><td align="center" valign="top" rowspan="1" colspan="1">1.4&#x02009;&#x000b1;&#x02009;0.5</td><td align="center" valign="top" rowspan="1" colspan="1">0.20</td><td align="center" valign="top" rowspan="1" colspan="1">0.56<xref ref-type="table-fn" rid="tfn1"><sup>a</sup></xref></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">LDL-C (mmol/l)</td><td align="center" valign="top" rowspan="1" colspan="1">3.7&#x02009;&#x000b1;&#x02009;1.0</td><td align="center" valign="top" rowspan="1" colspan="1">3.9&#x02009;&#x000b1;&#x02009;1.2</td><td align="center" valign="top" rowspan="1" colspan="1">0.18</td><td align="center" valign="top" rowspan="1" colspan="1">0.72<xref ref-type="table-fn" rid="tfn1"><sup>a</sup></xref></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Resistin (ng/mL)</td><td align="center" valign="top" rowspan="1" colspan="1">15.1&#x02009;&#x000b1;&#x02009;4.6</td><td align="center" valign="top" rowspan="1" colspan="1">15.2&#x02009;&#x000b1;&#x02009;3.7</td><td align="center" valign="top" rowspan="1" colspan="1">1.24</td><td align="center" valign="top" rowspan="1" colspan="1">0.15<xref ref-type="table-fn" rid="tfn1"><sup>a</sup></xref></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">HOMA-IR</td><td align="center" valign="top" rowspan="1" colspan="1">6.4&#x02009;&#x000b1;&#x02009;3.4</td><td align="center" valign="top" rowspan="1" colspan="1">6.6&#x02009;&#x000b1;&#x02009;3.5</td><td align="center" valign="top" rowspan="1" colspan="1">1.90</td><td align="center" valign="top" rowspan="1" colspan="1">0.26<xref ref-type="table-fn" rid="tfn1"><sup>a</sup></xref></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">HOMA-IS</td><td align="center" valign="top" rowspan="1" colspan="1">66.1&#x02009;&#x000b1;&#x02009;36.7</td><td align="center" valign="top" rowspan="1" colspan="1">68. 3&#x02009;&#x000b1;&#x02009;27.4</td><td align="center" valign="top" rowspan="1" colspan="1">1.55</td><td align="center" valign="top" rowspan="1" colspan="1">0.10<xref ref-type="table-fn" rid="tfn1"><sup>a</sup></xref></td></tr></tbody></table><table-wrap-foot><p><italic>One hundred and fifty-eight patients were assigned into an LBL group (LG, received 10&#x02009;mg LBL daily) and a control group (CG, received 10-mg placebo daily). There is not significant statistic difference at <italic>P</italic>&#x02009;&#x0003e;&#x02009;0.05</italic>.</p><fn id="tfn1"><p><italic><sup>a</sup>Paired t-test</italic>.</p></fn><fn id="tfn2"><p><italic><sup>b</sup>Chi-square test</italic>.</p></fn><p><italic>BMI, body mass index. HbA1c, hemoglobin A1c. FBG, fasting blood glucose. 2hPG, 2&#x02009;h postprandial plasma glucose. TC, total cholesterol. TG, triglyceride; HDL-C, high-density lipoprotein cholesterol. LDL-C, low-density lipoprotein cholesterol; HOMA-IR, homeostatic model assessment of &#x003b2;-cell function and insulin resistance; HOMA-IS, homeostatic model assessment of &#x003b2;-cell function and insulin sensitivity</italic>.</p></table-wrap-foot></table-wrap></sec><sec id="S3-3"><title>LBL Consumption Improves Biochemical Parameters and Lipid Pattern</title><p>Table <xref ref-type="table" rid="T2">2</xref> shows LBL-reduced insulin resistance and increased insulin sensitivity and secretory function when compared with the CG group (<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.05). LBL increased the level of HDL-C and reduced the levels of TG, total cholesterol (TC), and LDL-C (<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.05). The statistical differences were significant for lipid profiles between two groups (<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.05). Table <xref ref-type="table" rid="T3">3</xref> shows that LBL consumption reduced the serum levels of TG, TC, LDL-C, and MDA while increased the level of HDL-C after 4&#x02009;weeks. The statistical difference for the changes in the body weight of the patients was insignificant between two groups (LG, 64.9&#x02009;&#x000b1;&#x02009;8.4; CG, 68.7&#x02009;&#x000b1;&#x02009;11.3, <italic>P</italic>&#x02009;&#x0003e;&#x02009;0.05) after 4-week therapy. The values of HOMA-IR were lower in LG than in CG after therapy when compared with before therapy, whereas the values of HOMA-IS was higher in LG than in CG (<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.05). All the results suggest that LBL consumption significantly improves lipid patterns of GDM patients, reduces the HOMA-IR and increases the HOMA-IS.</p><table-wrap id="T2" position="float"><label>Table 2</label><caption><p>Parameters changes for antidiabetic activity in both groups.</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top" align="left" rowspan="2" colspan="1">Parameters</th><th valign="top" align="center" colspan="3" rowspan="1">LG (<italic>n</italic>&#x02009;=&#x02009;79)<hr/></th><th valign="top" align="center" colspan="3" rowspan="1">CG (<italic>n</italic>&#x02009;=&#x02009;79)<hr/></th><th valign="top" align="center" rowspan="2" colspan="1"><italic>P</italic>-values (LG <italic>via</italic> CG)</th></tr><tr><th valign="top" align="center" rowspan="1" colspan="1">Before</th><th valign="top" align="center" rowspan="1" colspan="1">After 4&#x02009;weeks</th><th valign="top" align="center" rowspan="1" colspan="1"><italic>P</italic>&#x02013;values</th><th valign="top" align="center" rowspan="1" colspan="1">Before</th><th valign="top" align="center" rowspan="1" colspan="1">After 4&#x02009;weeks</th><th valign="top" align="center" rowspan="1" colspan="1"><italic>P</italic>-values</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">FBG (mmol/L)</td><td align="center" valign="top" rowspan="1" colspan="1">8.3&#x02009;&#x000b1;&#x02009;1.1</td><td align="center" valign="top" rowspan="1" colspan="1">8.0&#x02009;&#x000b1;&#x02009;1.3</td><td align="center" valign="top" rowspan="1" colspan="1">0.21</td><td align="center" valign="top" rowspan="1" colspan="1">8.4&#x02009;&#x000b1;&#x02009;1.2</td><td align="center" valign="top" rowspan="1" colspan="1">8.3&#x02009;&#x000b1;&#x02009;1.2</td><td align="center" valign="top" rowspan="1" colspan="1">0.17</td><td align="center" valign="top" rowspan="1" colspan="1">0.32</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">2hPG (mmol/L)</td><td align="center" valign="top" rowspan="1" colspan="1">14.9&#x02009;&#x000b1;&#x02009;2.5</td><td align="center" valign="top" rowspan="1" colspan="1">14.0&#x02009;&#x000b1;&#x02009;3.2</td><td align="center" valign="top" rowspan="1" colspan="1">0.16</td><td align="center" valign="top" rowspan="1" colspan="1">14.1&#x02009;&#x000b1;&#x02009;3.2</td><td align="center" valign="top" rowspan="1" colspan="1">13.9&#x02009;&#x000b1;&#x02009;3.4</td><td align="center" valign="top" rowspan="1" colspan="1">0.27</td><td align="center" valign="top" rowspan="1" colspan="1">0.30</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">HbAlc (%)</td><td align="center" valign="top" rowspan="1" colspan="1">6.9&#x02009;&#x000b1;&#x02009;1.7</td><td align="center" valign="top" rowspan="1" colspan="1">6.4&#x02009;&#x000b1;&#x02009;1.9</td><td align="center" valign="top" rowspan="1" colspan="1">0.08</td><td align="center" valign="top" rowspan="1" colspan="1">6.7&#x02009;&#x000b1;&#x02009;1.9</td><td align="center" valign="top" rowspan="1" colspan="1">6.5&#x02009;&#x000b1;&#x02009;1.6</td><td align="center" valign="top" rowspan="1" colspan="1">0.41</td><td align="center" valign="top" rowspan="1" colspan="1">0.29</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Insulin (mIU/L)</td><td align="center" valign="top" rowspan="1" colspan="1">20.3&#x02009;&#x000b1;&#x02009;2.5</td><td align="center" valign="top" rowspan="1" colspan="1">52.7&#x02009;&#x000b1;&#x02009;6.8</td><td align="center" valign="top" rowspan="1" colspan="1">0.05</td><td align="center" valign="top" rowspan="1" colspan="1">20.7&#x02009;&#x000b1;&#x02009;2.4</td><td align="center" valign="top" rowspan="1" colspan="1">20.4&#x02009;&#x000b1;&#x02009;2.5</td><td align="center" valign="top" rowspan="1" colspan="1">0.34</td><td align="center" valign="top" rowspan="1" colspan="1">0.57</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Resistin (ng/mL)</td><td align="center" valign="top" rowspan="1" colspan="1">15.1&#x02009;&#x000b1;&#x02009;4.6</td><td align="center" valign="top" rowspan="1" colspan="1">12.1&#x02009;&#x000b1;&#x02009;3.2</td><td align="center" valign="top" rowspan="1" colspan="1">0.02</td><td align="center" valign="top" rowspan="1" colspan="1">15.2&#x02009;&#x000b1;&#x02009;3.0</td><td align="center" valign="top" rowspan="1" colspan="1">14.5&#x02009;&#x000b1;&#x02009;4.1</td><td align="center" valign="top" rowspan="1" colspan="1">0.14</td><td align="center" valign="top" rowspan="1" colspan="1">0.03</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">HOMA-IR</td><td align="center" valign="top" rowspan="1" colspan="1">6.4&#x02009;&#x000b1;&#x02009;3.4</td><td align="center" valign="top" rowspan="1" colspan="1">5.8&#x02009;&#x000b1;&#x02009;3.1</td><td align="center" valign="top" rowspan="1" colspan="1">0.04</td><td align="center" valign="top" rowspan="1" colspan="1">6.6&#x02009;&#x000b1;&#x02009;3.5</td><td align="center" valign="top" rowspan="1" colspan="1">6.4&#x02009;&#x000b1;&#x02009;2.9</td><td align="center" valign="top" rowspan="1" colspan="1">0.17</td><td align="center" valign="top" rowspan="1" colspan="1">0.04</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">HOMA-IS</td><td align="center" valign="top" rowspan="1" colspan="1">66.1&#x02009;&#x000b1;&#x02009;36.7</td><td align="center" valign="top" rowspan="1" colspan="1">74. 4&#x02009;&#x000b1;&#x02009;21.3</td><td align="center" valign="top" rowspan="1" colspan="1">0.03</td><td align="center" valign="top" rowspan="1" colspan="1">68. 3&#x02009;&#x000b1;&#x02009;27.4</td><td align="center" valign="top" rowspan="1" colspan="1">70.34&#x02009;&#x000b1;&#x02009;14.2</td><td align="center" valign="top" rowspan="1" colspan="1">0.24</td><td align="center" valign="top" rowspan="1" colspan="1">0.04</td></tr></tbody></table><table-wrap-foot><p><italic>One hundred and fifty-eight patients were assigned into an LBL group (LG, received 10-mg LBL daily) and a control group (CG, received 10-mg placebo daily)</italic>.</p></table-wrap-foot></table-wrap><table-wrap id="T3" position="float"><label>Table 3</label><caption><p>Comparison of lipid pattern in GDM patients before and after therapy.</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top" align="left" rowspan="1" colspan="1"/><th valign="top" align="left" rowspan="1" colspan="1"/><th valign="top" align="center" rowspan="1" colspan="1">Total lipids (g/L)</th><th valign="top" align="center" rowspan="1" colspan="1">TG (mmol/L)</th><th valign="top" align="center" rowspan="1" colspan="1">TC (mmol/L)</th><th valign="top" align="center" rowspan="1" colspan="1">HDL-C (mmol/L)</th><th valign="top" align="center" rowspan="1" colspan="1">LDL-C (mmol/L)</th><th valign="top" align="center" rowspan="1" colspan="1">MDA (mmol/L)</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="3" colspan="1">Before</td><td align="left" valign="top" rowspan="1" colspan="1">LG</td><td align="center" valign="top" rowspan="1" colspan="1">11.6&#x02009;&#x000b1;&#x02009;1.3</td><td align="center" valign="top" rowspan="1" colspan="1">2.8&#x02009;&#x000b1;&#x02009;1.2</td><td align="center" valign="top" rowspan="1" colspan="1">5.9&#x02009;&#x000b1;&#x02009;1.4</td><td align="center" valign="top" rowspan="1" colspan="1">1.3&#x02009;&#x000b1;&#x02009;0.3</td><td align="center" valign="top" rowspan="1" colspan="1">3.7&#x02009;&#x000b1;&#x02009;1.0</td><td align="center" valign="top" rowspan="1" colspan="1">1.7&#x02009;&#x000b1;&#x02009;0.3</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">CG</td><td align="center" valign="top" rowspan="1" colspan="1">11.2&#x02009;&#x000b1;&#x02009;1.1</td><td align="center" valign="top" rowspan="1" colspan="1">2.7&#x02009;&#x000b1;&#x02009;1.4</td><td align="center" valign="top" rowspan="1" colspan="1">5.7&#x02009;&#x000b1;&#x02009;1.6</td><td align="center" valign="top" rowspan="1" colspan="1">1.4&#x02009;&#x000b1;&#x02009;0.5</td><td align="center" valign="top" rowspan="1" colspan="1">3.9&#x02009;&#x000b1;&#x02009;1.2</td><td align="center" valign="top" rowspan="1" colspan="1">1.6&#x02009;&#x000b1;&#x02009;0.2</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"><italic>P</italic>-value</td><td align="center" valign="top" rowspan="1" colspan="1">0.45</td><td align="center" valign="top" rowspan="1" colspan="1">0.81</td><td align="center" valign="top" rowspan="1" colspan="1">0.40</td><td align="center" valign="top" rowspan="1" colspan="1">0.56</td><td align="center" valign="top" rowspan="1" colspan="1">0.72</td><td align="center" valign="top" rowspan="1" colspan="1">0.84</td></tr><tr><td align="left" valign="top" rowspan="3" colspan="1">4&#x02009;weeks</td><td align="left" valign="top" rowspan="1" colspan="1">LG</td><td align="center" valign="top" rowspan="1" colspan="1">8.2&#x02009;&#x000b1;&#x02009;0.7</td><td align="center" valign="top" rowspan="1" colspan="1">1.8&#x02009;&#x000b1;&#x02009;1.2</td><td align="center" valign="top" rowspan="1" colspan="1">4.6&#x02009;&#x000b1;&#x02009;1.1</td><td align="center" valign="top" rowspan="1" colspan="1">1.6&#x02009;&#x000b1;&#x02009;0.4</td><td align="center" valign="top" rowspan="1" colspan="1">3.0&#x02009;&#x000b1;&#x02009;1.2</td><td align="center" valign="top" rowspan="1" colspan="1">0.9&#x02009;&#x000b1;&#x02009;0.2</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">CG</td><td align="center" valign="top" rowspan="1" colspan="1">10.9&#x02009;&#x000b1;&#x02009;1.0</td><td align="center" valign="top" rowspan="1" colspan="1">2.6&#x02009;&#x000b1;&#x02009;1.4</td><td align="center" valign="top" rowspan="1" colspan="1">5.5&#x02009;&#x000b1;&#x02009;1.0</td><td align="center" valign="top" rowspan="1" colspan="1">1.2&#x02009;&#x000b1;&#x02009;0.3</td><td align="center" valign="top" rowspan="1" colspan="1">3.9&#x02009;&#x000b1;&#x02009;1.3</td><td align="center" valign="top" rowspan="1" colspan="1">1.6&#x02009;&#x000b1;&#x02009;0.4</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"><italic>P</italic>-value</td><td align="center" valign="top" rowspan="1" colspan="1">0.02<xref ref-type="table-fn" rid="tfn3">*</xref></td><td align="center" valign="top" rowspan="1" colspan="1">0.01<xref ref-type="table-fn" rid="tfn3">*</xref></td><td align="center" valign="top" rowspan="1" colspan="1">0.02<xref ref-type="table-fn" rid="tfn3">*</xref></td><td align="center" valign="top" rowspan="1" colspan="1">0.01<xref ref-type="table-fn" rid="tfn3">*</xref></td><td align="center" valign="top" rowspan="1" colspan="1">0.01<xref ref-type="table-fn" rid="tfn3">*</xref></td><td align="center" valign="top" rowspan="1" colspan="1">0.01<xref ref-type="table-fn" rid="tfn3">*</xref></td></tr></tbody></table><table-wrap-foot><p><italic>One hundred and fifty-eight patients were assigned into an LBL group (LG, received 10-mg LBL daily) and a control group (CG, received 10-mg placebo daily)</italic>.</p><fn id="tfn3"><p><italic>*P&#x02009;&#x0003c;&#x02009;0.05 via CG</italic>.</p></fn><p><italic>MDA, malondialdehyde</italic>.</p></table-wrap-foot></table-wrap></sec><sec id="S3-4"><title>LBL Consumption Reduces Serum miR-33 Level and Relative mRNA Level of SREBPF1, and Increases the Level of ABCA1</title><p>The statistical difference was insignificant for relative mRNA levels of miR-33 (Figure <xref ref-type="fig" rid="F3">3</xref>A), ABCA1 (Figure <xref ref-type="fig" rid="F3">3</xref>B), and SREBF1 (Figure <xref ref-type="fig" rid="F3">3</xref>B) between two groups (<italic>P</italic>&#x02009;&#x0003e;&#x02009;0.05). The serum levels of miR-33 and SREBF1 were decreased while ABCA1 level was increased in LBLG when compared with CG after 4-week LBL consumption (Figures <xref ref-type="fig" rid="F3">3</xref>A,B, <italic>P</italic>&#x02009;&#x0003c;&#x02009;0.05). The results suggest that long-term LBL consumption can affect GDM by reducing the serum mRNA levels miR-33 and SREBF1, and increasing the mRNA level of ABCA1.</p><fig id="F3" position="float"><label>Figure 3</label><caption><p><italic>Lycium barbarum L</italic>. (LBL) consumption significantly reduces miR-33 level and the level of sterol regulatory element-binding transcription 1 (SREBPF1) and increases the level of ABCA1 in gestational diabetes mellitus (GDM) patients. <bold>(A)</bold> The effects of LBL on miR-33 level. <bold>(B)</bold> The effects of LBL on relative mRNA levels of ABCA1 and SREBF1. LG-B, the GDM patients before receiving LBL treatment. CG-B, the GDM patients before receiving placebo. LG-A, the GDM patients after receiving 4-week LBL treatment. CG-A, the GDM patients after receiving 4-week placebo. <bold>(C)</bold> LBL consumption significantly reduces protein level of SREBPF1 and increases the level of ABCA1 in GDM patients. All data were presented as mean values&#x02009;&#x000b1;&#x02009;SD. There were statistically significant differences if *<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.05 vs. a control group.</p></caption><graphic xlink:href="fendo-09-00049-g003"/></fig></sec><sec id="S3-5"><title>LBL Consumption Significantly Reduces Relative Protein Levels of SREBPF1 and Increases the Level of ABCA1</title><p>The statistical difference was insignificant for relative protein levels of ABCA1 and SREBF1 among four groups (Figure <xref ref-type="fig" rid="F3">3</xref>C, <italic>P</italic>&#x02009;&#x0003e;&#x02009;0.05). The protein level of SREBF1 was decreased and the level of ABCA1 was increased in LG when compared with CG after 4-week LBL consumption (Figure <xref ref-type="fig" rid="F3">3</xref>C, <italic>P</italic>&#x02009;&#x0003c;&#x02009;0.05). The results suggest that long-term LBL consumption can affect GDM by reducing protein level of SREBF1, and increasing the protein level of ABCA1.</p></sec><sec id="S3-6"><title>MiR-33 Level Is Associated with Lipid Components</title><p>Spearman&#x02019;s Rank-Order Correlation Test showed that the increase in relative level of miR-33 resulted in the increase in the concentrations of TG (Figure <xref ref-type="fig" rid="F4">4</xref>A), TC (Figure <xref ref-type="fig" rid="F4">4</xref>B), and LDL-C (Figure <xref ref-type="fig" rid="F4">4</xref>D) and decrease in the concentration of HDL-C (Figure <xref ref-type="fig" rid="F4">4</xref>C). There was a strong positive association between miR-33 level and TG, or TC and or LDL-C, and a strong negative association between miR-33 level and HDL-C (<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.05). These results suggest there is a strong association between serum miR-33 level and lipid components.</p><fig id="F4" position="float"><label>Figure 4</label><caption><p>The analysis of spearman&#x02019;s rank correlation coefficient for the relationship between serum miR-33 level and serum lipid profiles. <bold>(A)</bold> The relationship between serum miR-33 level and triglyceride (TG) concentrations. <bold>(B)</bold> The relationship between serum miR-33 level and total cholesterol (TC) concentrations. <bold>(C)</bold> The relationship between serum miR-33 level and high-density lipoprotein cholesterol (HDL-C) concentrations. <bold>(D)</bold> The relationship between serum miR-33 level and low-density lipoprotein cholesterol (LDL-C) concentrations. Spearman&#x02019;s Rho is used to measure the strength of association between two variables, where the value <italic>r</italic> falls between 0.5 and 1 means a strong positive correlation and the value <italic>r</italic> falls between &#x02212;1 and &#x02212;0.5 means a strong negative correlation.</p></caption><graphic xlink:href="fendo-09-00049-g004"/></fig></sec><sec id="S3-7"><title>Effects of LBLP IV on Insulin Secretion</title><p>As shown in Figure <xref ref-type="fig" rid="F5">5</xref>, LBP IV increased insulin secretion from 20.6&#x02009;&#x000b1;&#x02009;2.6&#x02009;ng/mL (basal levels) to 52.7&#x02009;&#x000b1;&#x02009;6.8&#x02009;ng/mL. Under the same situations, LBLP I, II, and III could not cause significant changes for insulin secretion in SW1990 cells. The results suggest that LBLP IV may be the major bioactive ingredient of LBL for the therapy of GDM patients.</p><fig id="F5" position="float"><label>Figure 5</label><caption><p>Polysaccharides of <italic>Lycium barbarum L</italic>. (LBL) activate insulin secretion in SW1990 cells. Values were represented as the means&#x02009;&#x000b1;&#x02009;SD. from eight experiments. There were statistically significant differences if *<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.05. LBL, the extracts of <italic>LB</italic>L with four main polysaccharides (LBLP I, II, III, and IV).</p></caption><graphic xlink:href="fendo-09-00049-g005"/></fig></sec><sec id="S3-8"><title>LBLP IV from LBL Significantly Reduces miR-33 Level, and Relative mRNA Level of SREBPF1, and Increases the Level of ABCA1</title><p>To explore the specific function of LBL components, four polysaccharides were purified and tested to their effects on human pancreatic carcinoma cell SW1990. Real time qRT-PCR showed that LBLP I could not affect miR-33 levels (Figure <xref ref-type="fig" rid="F6">6</xref>A, <italic>P</italic>&#x02009;&#x0003e;&#x02009;0.05) while LBLP II and III increased miR-33 level, and LBLP IV and LBL reduced miR-33 level significantly (<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.05) when compared with controls. On the other hand, LBLP I, II and III reduced while LBL and LBLP IV increased relative mRNA levels of ABCA1 (Figure <xref ref-type="fig" rid="F6">6</xref>B, <italic>P</italic>&#x02009;&#x0003c;&#x02009;0.05). Comparatively, LBL and LBLP IV reduced more relative mRNA levels of SREBF1 than other polysaccharides (Figure <xref ref-type="fig" rid="F6">6</xref>B, <italic>P</italic>&#x02009;&#x0003c;&#x02009;0.05). There were no changes for miR-33 levels when the cells were transfected with scrambled miRNA when compared with the cells without transfection (Figure <xref ref-type="fig" rid="F6">6</xref>C). In the similar cases, there were no changes for ABCA1 and SREBF1 levels when the cells were transfected with scrambled miRNA when compared with the cells without transfection (Figure <xref ref-type="fig" rid="F6">6</xref>D). By contrast, miR-33 levels reached the highest level or the lowest level, and were almost same in all groups when the gene was overexpressed (Figure <xref ref-type="fig" rid="F6">6</xref>E) or silenced (Figure <xref ref-type="fig" rid="F6">6</xref>G). All the results suggest that LBLP IV from LBL significantly reduces miR-33 level, and relative mRNA level of SREBF1, and increases the level of ABCA1. LBLP IV could not affect the levels of ABCA1 and SREBF1 anymore when miR-33 was overexpressed (Figure <xref ref-type="fig" rid="F6">6</xref>F, <italic>P</italic>&#x02009;&#x0003e;&#x02009;0.05) or silenced (Figure <xref ref-type="fig" rid="F6">6</xref>H, <italic>P</italic>&#x02009;&#x0003c;&#x02009;0.05). The levels of miR-33 had negative relation with ABCA1 and positive relation with SREBF1 (Figure <xref ref-type="fig" rid="F6">6</xref>). ABCA1 has negative relation with TG, TC, and LDL-C and positive relation with HDL-C (Figure <xref ref-type="fig" rid="F6">6</xref>; Table <xref ref-type="table" rid="T3">3</xref>). Inversely, SREBF1 had positive relation with TG, TC, and LDL-C and negative relation with HDL-C (Figure <xref ref-type="fig" rid="F6">6</xref>; Table <xref ref-type="table" rid="T3">3</xref>). The results suggest LBLP IV affect the levels of ABCA1 and SREBF1 by regulating miR-33 levels.</p><fig id="F6" position="float"><label>Figure 6</label><caption><p>LBLP IV reduces miR-33 level and mRNA level of SREBPF1 and increases the level of ABCA1 in human pancreatic carcinoma cell SW1990. <bold>(A)</bold> The effects of different polysaccharide on miR-33 level. <bold>(B)</bold> The effects of different polysaccharides on relative mRNA levels of ABCA1 and SREBF1. <bold>(C)</bold> The effects of scrambled miRNA on miR-33 level. <bold>(D)</bold> The effects of scrambled miRNA on relative mRNA levels of ABCA1 and SREBF1. <bold>(E)</bold> The effects of miR-33 overexpression on miR-33 level. <bold>(F)</bold> The effects of miR-33 overexpression on relative mRNA levels of ABCA1 and SREBF1. <bold>(G)</bold> The effects of miR-33 silence on miR-33 level. <bold>(H)</bold> The effects of miR-33 silence on relative mRNA levels of ABCA1 and SREBF1. All data were presented as mean values&#x02009;&#x000b1;&#x02009;SD. There were statistically significant differences if *<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.05 and **<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.001 vs. a control group.</p></caption><graphic xlink:href="fendo-09-00049-g006"/></fig></sec><sec id="S3-9"><title>LBLP IV from LBL Significantly Reduces Relative Protein Level of SREBPF1, and Increases the Level of ABCA1</title><p>Real-time qRT-PCR showed that LBLP I, II, and III reduced while LBL and LBLP IV increased protein levels of ABCA1 (Figure <xref ref-type="fig" rid="F7">7</xref>A, <italic>P</italic>&#x02009;&#x0003c;&#x02009;0.05). Comparatively, LBL and LBLP IV reduced relative protein levels of SREBF1 whereas LBLP I, II and III increased the levels of SREBF1 (Figure <xref ref-type="fig" rid="F7">7</xref>A, <italic>P</italic>&#x02009;&#x0003c;&#x02009;0.05). All the results suggest that LBLP IV and LBL significantly reduce relative protein level of SREBF1, and increase the level of ABCA1. There were no changes for relative protein level of SREBF1 and ABCA1 when the cells were transfected with scrambled miRNA when compared with the cells without transfection (Figures <xref ref-type="fig" rid="F7">7</xref>A,B). LBLP IV could not affect the levels of ABCA1 and SREBF1 anymore when miR-33 was overexpressed (Figure <xref ref-type="fig" rid="F7">7</xref>C, <italic>P</italic>&#x02009;&#x0003e;&#x02009;0.05) or silenced (Figure <xref ref-type="fig" rid="F7">7</xref>D, <italic>P</italic>&#x02009;&#x0003e;&#x02009;0.05). The results suggest LBLP IV affects the protein levels of ABCA1 and SREBF1 by regulating miR-33 level.</p><fig id="F7" position="float"><label>Figure 7</label><caption><p>Polysaccharides of <italic>Lycium barbarum L</italic>. (LBLP) IV reduces protein level of sterol regulatory element-binding transcription 1 (SREBPF1) and increases the level of ABCA1 in human pancreatic carcinoma cell SW1990. <bold>(A)</bold> The effects of different polysaccharide on relative protein levels of ABCA1 and SREBF1. <bold>(B)</bold> The effects of scrambled miRNA on protein levels of ABCA1 and SREBF1. <bold>(C)</bold> The effects of miR-33 overexpression on protein levels of ABCA1 and SREBF1. <bold>(D)</bold> The effects of miR-33 silence on protein levels of ABCA1 and SREBF1. All data were presented as mean values&#x02009;&#x000b1;&#x02009;SD. There were statistically significant differences if *<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.05 and **<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.001 vs. a control group.</p></caption><graphic xlink:href="fendo-09-00049-g007"/></fig></sec></sec><sec sec-type="discussion" id="S4"><title>Discussion</title><p><italic>Lycium barbarum L</italic>. has been reported to have potential anti-inflammatory (<xref rid="B45" ref-type="bibr">45</xref>) and anticarcinogenic applications (<xref rid="B46" ref-type="bibr">46</xref>), and attenuate lipid peroxidation (<xref rid="B47" ref-type="bibr">47</xref>), and diverse health protecting benefits (<xref rid="B48" ref-type="bibr">48</xref>). Furthermore, LBLP IV can treat diabetic rats and it can be developed as a potential dietary therapeutic agent in the treatment of diabetes (<xref rid="B30" ref-type="bibr">30</xref>). Present findings demonstrate that the LBLP IV is the major compound in LBL and shows significant antidiabetic activities for GDM. More importantly, LBLP IV promotes the insulin secretion (Figure <xref ref-type="fig" rid="F5">5</xref>), which is beneficial for GDM patients. LBLP IV has been found to reduce serum level of miR-33.</p><p>Hepatic mRNA and protein expression of lipid-related genes have been reported to be associated with miRNAs (<xref rid="B49" ref-type="bibr">49</xref>). The administration of LBL significantly reduced serum TC and TG levels but increased the HDL-C content (Table <xref ref-type="table" rid="T3">3</xref>). The mRNA and protein expression level of ABCA1 were upregulated and SREBF1 was down-regulated (Figures <xref ref-type="fig" rid="F6">6</xref> and <xref ref-type="fig" rid="F7">7</xref>). Furthermore, the expression levels of miR-33, which directly modulate ABCA1 and SREBF1, which indirectly regulates fatty acid synthase (FAS) (<xref rid="B50" ref-type="bibr">50</xref>, <xref rid="B51" ref-type="bibr">51</xref>). The repression of miR-33 is a possible molecular mechanism of the hypolipidemic effects of LBLP IV in the liver. Compared with LBLP IV, the three compounds (LBLP I, II, and III) of LBL cannot reduce serum level of miR-33, which regulate ABCA1 and SREBF1, and closely associated with lipid metabolism.</p><p>Although LBLP IV was proven to be a bioactive compound from LBL, it could not be made on a large scale. Thus, LBL was still used in subsequent experiment in GDM patients. The changes of biochemical composition indicated that LBL consumption reduced insulin resistance, increased insulin secretory function (Table <xref ref-type="table" rid="T2">2</xref>; Figure <xref ref-type="fig" rid="F5">5</xref>) and improved a lipid profiles (Table <xref ref-type="table" rid="T3">3</xref>). Notably, LBL showed a better result after 4&#x02009;weeks. In contrast, long-term consumption of LBL polysaccharides significantly ameliorates diabetes, including the improvement of general well-being and the decrease of the levels of HbA1c (<xref rid="B52" ref-type="bibr">52</xref>), FBG (<xref rid="B53" ref-type="bibr">53</xref>), and body mass index (BMI) (<xref rid="B54" ref-type="bibr">54</xref>). Similarly, LBL has the functions for controlling the levels of BMI and BG.</p><p>The reasons for the functions of LBL are complex. According to Chinese theory, LBL can transfer the strength between deficiency and excess from different parts of human body, including upper and lower limbs, internal organs and environment. Full-body and cooperation among different organs are the main ideas of LBL. Differentiation and development genes were repressed by embryonic stem cell-enriched miRNAs, which maintained the stem cell state. MicroRNA level has been reported to be affected by vitamin C (<xref rid="B55" ref-type="bibr">55</xref>), polyphenols (<xref rid="B56" ref-type="bibr">56</xref>), flavone (<xref rid="B57" ref-type="bibr">57</xref>), and polysaccharide (<xref rid="B58" ref-type="bibr">58</xref>). Composition analysis of LBL showed that polysaccharides were rich. The results suggest LBLP IV improves antidiabetic capabilities of GDM patients.</p><p>Polysaccharides of LBL IV reduced serum level of miR-33, which regulated ABCA1 and SREBP1. The latter two molecules affected lipid metabolism. Thus, LBLP IV improved lipid profiles may by affecting serum miR-33. To approve that, miR-33 was overexpressed and silenced, and the levels of ABCA1 and SREBF1 were significantly changed too (Figures <xref ref-type="fig" rid="F6">6</xref> and <xref ref-type="fig" rid="F7">7</xref>). However, the LBLP IV treatment could not change these molecules anymore. The results suggest that LBLP IV improves lipid profiles by regulating the levels of ABCA1 and SERBF1 <italic>via</italic> miR-33.</p><p>The present findings showed that LBLP IV reduced the level of SREBF1 <italic>via</italic> miR-33. The variants of SREBF1 have been found to be discreetly associated with hyperglycemia because of the reduction in insulin sensitivity. SREBF1 is a mediator of insulin action and can affect normal insulin secretion (<xref rid="B59" ref-type="bibr">59</xref>). Moreover, the SNP of SREBF1 is closely related to insulin resistance (<xref rid="B60" ref-type="bibr">60</xref>). SREBF1 also regulates resistin expression (<xref rid="B61" ref-type="bibr">61</xref>). Resistin regulates insulin secretion and glucagon from beta or alpha cells, and pancreatic islets (<xref rid="B62" ref-type="bibr">62</xref>). Thus, LBLP IV treatment will affect insulin secretion, HOMA-IR and resistin levels. On the other hand, overexpression of SREBP1 will increase fatty acid synthesis and triacylglycerol accumulation (<xref rid="B63" ref-type="bibr">63</xref>) and regulate fatty acid oxidation by activating acetyl coenzyme a carboxylase 2 (<xref rid="B64" ref-type="bibr">64</xref>). Although the decrease of SREBF1 can be caused by LBLP-II and &#x02013;III since the oligosaccharides also regulate miR-33 and the close relationship occurs between miR-33 and SREBF1, the decreased degree was still lower than that caused by LBLP-IV. The result will lead to no significant difference for the changes of lipid profiles when compared with controls.</p><p>In the past decades, the multitarget of miRNA has caught much interest. miRNA has become a critical factor for regulating lipoprotein (<xref rid="B65" ref-type="bibr">65</xref>). Lipid metabolism is a main cause of GDM (<xref rid="B66" ref-type="bibr">66</xref>) and there is increasing evidence that miRNA plays an important role in lipid metabolism (<xref rid="B67" ref-type="bibr">67</xref>). miRNA can control LDL-C level by regulating TR4 expression in ox-LDL-induced macrophages, and thus affect lipid accumulation (<xref rid="B68" ref-type="bibr">68</xref>). miRNA also control LDL-C level by regulating the genes, which are associated with very LDL secretion, cholesterol synthesis, and LDL receptor. Interestingly, several of these miRNAs are located in genomic loci associated with abnormal levels of circulating lipids in humans. MiRNA is a potential drug potential for affecting cholesterol and TG levels in patients (<xref rid="B69" ref-type="bibr">69</xref>).</p><p>However, the exact molecular mechanism for the effects of LBLP IV on the level of miR-33 remains unknown. There may be the following possible mechanisms: (1) some factors promote microRNA expression by binding miRNA precursor <italic>via</italic> stem-loop recognition (<xref rid="B70" ref-type="bibr">70</xref>). LBLP IV may promote microRNA expression by binding miR-33 precursor <italic>via</italic> stem-loop recognition. (2) The relation between amplification and deletion of miRNA binding sites, 3&#x02032; UTR length, and miRNA expression has been reported (<xref rid="B71" ref-type="bibr">71</xref>). Thus, the site can also be explored to detect the interaction between LBLP IV and miR-33. (3) There is the evidence of the miRNA promoter modification may be a critical determinant of overexpression of miRNA. Restored the hypermethylated promoter can decrease target mRNA and proteins levels (<xref rid="B72" ref-type="bibr">72</xref>). Oligosaccharide has an epigenetic effect on gene expression by inhibiting the de-methylation of a &#x0201c;CpG&#x0201d; island within the promoter (<xref rid="B73" ref-type="bibr">73</xref>).</p><p>There were some limitations to the present study: (1) SW1990 is derived from a spleen metastasis of a grade II pancreatic adenocarcinoma derived from the exocrine pancreas. It is not a representable for a GDM model. A better clinical sample should be applied in this case for analysis. For example, placenta is responsible for transporting nutrients, gasses, and cytokines to the fetu, and eliminate wastes. Thus, normal placental development is very important for the fetus and mother. Trophoblast are the main cells of placenta and primary mouse placental trophoblast cells will be a useful tool to study placental development trophoblast at specific stages of pregnancy (<xref rid="B74" ref-type="bibr">74</xref>). Further work shows that Serotonin (5-HT) transporter (SERT) can affect 5-HT concentration in placenta. In GDM, free plasma 5-HT levels are increased because the 5-HT uptake is remarkably reduced, which is caused by impairment in translocating SERT to cell surface. Regular expression of SERT of trophoblast will be beneficial to alleviate GDM-associated complications (<xref rid="B75" ref-type="bibr">75</xref>). By using human placenta, the changes of functional SLC6A4 polymorphisms have been found to be associated with long-term outcomes of infants exposed to GDM (<xref rid="B76" ref-type="bibr">76</xref>). Insulin signaling is often required for maintaining normal function of SERT on cytoplasma membrane of the trophoblast in placenta. The findings from clinical samples demonstrate that in GDM-associated defect on insulin receptor would change 5-HT uptake rates (<xref rid="B77" ref-type="bibr">77</xref>). (2) LBL consumption should be performed in a larger population since the shows little side effects. (3) LBLP IV is the major ingredient in LBL but it is still difficult to determine other components of LBL, which must be determined in the future studies. (4) LBLP IV could not be produced on a larger scale from LBL and LBL was still used in the present study. (5) Some conclusions needed to be confirmed by using broad samples, since only blood serum samples were used in this case. Further work is highly demanded to address these issues.</p></sec><sec id="S5"><title>Conclusion</title><p>Long-term LBL consumption was beneficial for improving some symptoms of GDM. However, LBL may have a lot of good or bad effect on GDM because of without the complete examinations for its effects on all aspects or symptoms of GDM. The rehabilitate functions of LBLP IV from LBL may improve lipid profiles. The changes for the level of TG, TC, HDL-C, LDL-C, and MDA also increase antioxidant activity of GDM patients. Furthermore, LBLP IV in LBL plays an important role in antidiabetic activities in GDM patients. Further work is highly demanded to make sure LBL consumption as non-pharmaceutical intervention for preventing the risk or progression of GDM.</p></sec><sec id="S6"><title>Ethics Statement</title><p>All protocols were approved by ethical committee of our hospital (Approval no. 201602X4), and the study was carried out according to the principles described in the World Medical Association Declaration of Helsinki. All subjects gave written informed consent in accordance with the Declaration of Helsinki.</p></sec><sec id="S7"><title>Author Contributions</title><p>SY and LF performed the experiments. LS, WJ, and HP designed the experiment and analyzed all data. RL wrote the article. All authors approved the final submission in this journal.</p></sec><sec id="S8"><title>Conflict of Interest Statement</title><p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p></sec></body><back><ack><p>We are very grateful to two reviewers for their critical and strategic comments, which have significantly improved the quality of the present article.</p></ack><ref-list><title>References</title><ref id="B1"><label>1</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Ge</surname><given-names>ZP</given-names></name><name><surname>Sun</surname><given-names>LZ</given-names></name><name><surname>Tong</surname><given-names>P</given-names></name><name><surname>Lu</surname><given-names>HM</given-names></name></person-group>. <article-title>Genetic variation of rs3811463 is associated with gestational diabetes mellitus susceptibility</article-title>. <source>Exp Ther Med</source> (<year>2017</year>) <volume>14</volume>:<fpage>5157</fpage>&#x02013;<lpage>62</lpage>.<pub-id pub-id-type="doi">10.3892/etm.2017.5188</pub-id><pub-id pub-id-type="pmid">29201231</pub-id></mixed-citation></ref><ref id="B2"><label>2</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guillen-Sacoto</surname><given-names>MA</given-names></name><name><surname>Barquiel</surname><given-names>B</given-names></name><name><surname>Hillman</surname><given-names>N</given-names></name><name><surname>Burgos</surname><given-names>MA</given-names></name><name><surname>Herranz</surname><given-names>L</given-names></name></person-group>
<article-title>Metabolic syndrome and impaired glucose metabolism during early postpartum after twin pregnancies complicated by gestational diabetes mellitus: is the risk comparable to singleton pregnancies?</article-title>
<source>Diabetes Metab</source> (<year>2017</year>) <volume>S1262-3636</volume>(<issue>17</issue>):<fpage>30549</fpage>&#x02013;<lpage>30549</lpage>.<pub-id pub-id-type="doi">10.1016/j.diabet.2017.10.008</pub-id></mixed-citation></ref><ref id="B3"><label>3</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Chi</surname><given-names>H</given-names></name><name><surname>Xiao</surname><given-names>H</given-names></name><name><surname>Tian</surname><given-names>X</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Yun</surname><given-names>X</given-names></name><etal/></person-group>
<article-title>Interleukin 6 (IL-6) and tumor necrosis factor alpha (TNF-alpha) single nucleotide polymorphisms (SNPs), inflammation and metabolism in gestational diabetes mellitus in inner Mongolia</article-title>. <source>Med Sci Monit</source> (<year>2017</year>) <volume>23</volume>:<fpage>4149</fpage>&#x02013;<lpage>57</lpage>.<pub-id pub-id-type="doi">10.12659/MSM.903565</pub-id><pub-id pub-id-type="pmid">28846666</pub-id></mixed-citation></ref><ref id="B4"><label>4</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Metzger</surname><given-names>BE</given-names></name><name><surname>Coustan</surname><given-names>DR</given-names></name></person-group>
<article-title>Summary and recommendations of the fourth international workshop-conference on gestational diabetes mellitus. The organizing committee</article-title>. <source>Diabetes Care</source> (<year>1998</year>) <volume>21</volume>(<issue>Suppl 2</issue>):<fpage>B161</fpage>&#x02013;<lpage>7</lpage>.<pub-id pub-id-type="pmid">9704245</pub-id></mixed-citation></ref><ref id="B5"><label>5</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yilmaz</surname><given-names>H</given-names></name><name><surname>Celik</surname><given-names>HT</given-names></name><name><surname>Namuslu</surname><given-names>M</given-names></name><name><surname>Inan</surname><given-names>O</given-names></name><name><surname>Onaran</surname><given-names>Y</given-names></name><name><surname>Karakurt</surname><given-names>F</given-names></name><etal/></person-group>
<article-title>Benefits of the neutrophil-to-lymphocyte ratio for the prediction of gestational diabetes mellitus in pregnant women</article-title>. <source>Exp Clin Endocrinol Diabetes</source> (<year>2014</year>) <volume>122</volume>:<fpage>39</fpage>&#x02013;<lpage>43.1</lpage>.<pub-id pub-id-type="doi">10.1055/s-0033-1361087</pub-id><pub-id pub-id-type="pmid">24464596</pub-id></mixed-citation></ref><ref id="B6"><label>6</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mathiesen</surname><given-names>ER</given-names></name><name><surname>Andersen</surname><given-names>H</given-names></name><name><surname>Kring</surname><given-names>SI</given-names></name><name><surname>Damm</surname><given-names>P</given-names></name></person-group>. <article-title>Design and rationale of a large, international, prospective cohort study to evaluate the occurrence of malformations and perinatal/neonatal death using insulin detemir in pregnant women with diabetes in comparison with other long-acting insulins</article-title>. <source>BMC Pregnancy Childbirth</source> (<year>2017</year>) <volume>17</volume>:<fpage>38.1</fpage>.<pub-id pub-id-type="doi">10.1186/s12884-016-1177-4</pub-id><pub-id pub-id-type="pmid">28100192</pub-id></mixed-citation></ref><ref id="B7"><label>7</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Starikov</surname><given-names>R</given-names></name><name><surname>Dudley</surname><given-names>D</given-names></name><name><surname>Reddy</surname><given-names>UM</given-names></name></person-group>
<article-title>Stillbirth in the pregnancy complicated by diabetes</article-title>. <source>Curr Diab Rep</source> (<year>2015</year>) <volume>15</volume>:<fpage>11.1</fpage><pub-id pub-id-type="doi">10.1007/s11892-015-0580-y</pub-id><pub-id pub-id-type="pmid">25667005</pub-id></mixed-citation></ref><ref id="B8"><label>8</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Luo</surname><given-names>ZC</given-names></name><name><surname>Zhao</surname><given-names>YJ</given-names></name><name><surname>Ouyang</surname><given-names>F</given-names></name><name><surname>Yang</surname><given-names>ZJ</given-names></name><name><surname>Guo</surname><given-names>YN</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name></person-group>. <article-title>Diabetes and perinatal mortality in twin pregnancies</article-title>. <source>PLoS One</source> (<year>2013</year>) <volume>8</volume>:<fpage>e75354.1</fpage>.<pub-id pub-id-type="doi">10.1371/journal.pone.0075354</pub-id><pub-id pub-id-type="pmid">24058678</pub-id></mixed-citation></ref><ref id="B9"><label>9</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sadlecki</surname><given-names>P</given-names></name><name><surname>Grabiec</surname><given-names>M</given-names></name><name><surname>Walentowicz-Sadlecka</surname><given-names>M</given-names></name></person-group>. <article-title>Prenatal clinical assessment of NT-proBNP as a diagnostic tool for preeclampsia, gestational hypertension and gestational diabetes mellitus</article-title>. <source>PLoS One</source> (<year>2016</year>) <volume>11</volume>:<fpage>e0162957.1</fpage>.<pub-id pub-id-type="doi">10.1371/journal.pone.0162957</pub-id><pub-id pub-id-type="pmid">27685993</pub-id></mixed-citation></ref><ref id="B10"><label>10</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vedra</surname><given-names>B</given-names></name></person-group>
<article-title>Diagnosis of asymptomatic diabetes following the delivery of excessively large fetus</article-title>. <source>Cesk Gynekol</source> (<year>1970</year>) <volume>35</volume>:<fpage>227</fpage>&#x02013;<lpage>30</lpage>.<pub-id pub-id-type="pmid">5420260</pub-id></mixed-citation></ref><ref id="B11"><label>11</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McNamee</surname><given-names>MB</given-names></name><name><surname>Cardwell</surname><given-names>CR</given-names></name><name><surname>Patterson</surname><given-names>CC</given-names></name></person-group>. <article-title>Neonatal jaundice is associated with a small increase in the risk of childhood type 1 diabetes: a meta-analysis of observational studies</article-title>. <source>Acta Diabetol</source> (<year>2012</year>) <volume>49</volume>:<fpage>83</fpage>&#x02013;<lpage>7</lpage>.<pub-id pub-id-type="doi">10.1007/s00592-011-0326-5</pub-id><pub-id pub-id-type="pmid">21984049</pub-id></mixed-citation></ref><ref id="B12"><label>12</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ho</surname><given-names>FL</given-names></name><name><surname>Liew</surname><given-names>CF</given-names></name><name><surname>Cunanan</surname><given-names>EC</given-names></name><name><surname>Lee</surname><given-names>KO</given-names></name></person-group>. <article-title>Oral hypoglycaemic agents for diabetes in pregnancy&#x02014;an appraisal of the current evidence for oral anti-diabetic drug use in pregnancy</article-title>. <source>Ann Acad Med Singapore</source> (<year>2007</year>) <volume>36</volume>:<fpage>672</fpage>&#x02013;<lpage>8</lpage>.10.1.1.550.5713<pub-id pub-id-type="pmid">17767338</pub-id></mixed-citation></ref><ref id="B13"><label>13</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Karamali</surname><given-names>M</given-names></name><name><surname>Asemi</surname><given-names>Z</given-names></name><name><surname>Ahmadi-Dastjerdi</surname><given-names>M</given-names></name><name><surname>Esmaillzadeh</surname><given-names>A</given-names></name></person-group>. <article-title>Calcium plus vitamin D supplementation affects pregnancy outcomes in gestational diabetes: randomized, double-blind, placebo-controlled trial</article-title>. <source>Public Health Nutr</source> (<year>2016</year>) <volume>19</volume>:<fpage>156</fpage>&#x02013;<lpage>63</lpage>.<pub-id pub-id-type="doi">10.1017/S1368980015000609</pub-id><pub-id pub-id-type="pmid">25790761</pub-id></mixed-citation></ref><ref id="B14"><label>14</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mizuno</surname><given-names>S</given-names></name><name><surname>Nishigori</surname><given-names>H</given-names></name><name><surname>Sugiyama</surname><given-names>T</given-names></name><name><surname>Takahashi</surname><given-names>F</given-names></name><name><surname>Iwama</surname><given-names>N</given-names></name><name><surname>Watanabe</surname><given-names>Z</given-names></name><etal/></person-group>
<article-title>Association between social capital and the prevalence of gestational diabetes mellitus: an interim report of the Japan environment and children&#x02019;s study</article-title>. <source>Diabetes Res Clin Pract</source> (<year>2016</year>) <volume>120</volume>:<fpage>132</fpage>&#x02013;<lpage>41</lpage>.<pub-id pub-id-type="doi">10.1016/j.diabres.2016.07.020</pub-id><pub-id pub-id-type="pmid">27544908</pub-id></mixed-citation></ref><ref id="B15"><label>15</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moosazadeh</surname><given-names>M</given-names></name><name><surname>Asemi</surname><given-names>Z</given-names></name><name><surname>Lankarani</surname><given-names>KB</given-names></name><name><surname>Tabrizi</surname><given-names>R</given-names></name><name><surname>Maharlouei</surname><given-names>N</given-names></name><name><surname>Naghibzadeh-Tahami</surname><given-names>A</given-names></name><etal/></person-group>
<article-title>Family history of diabetes and the risk of gestational diabetes mellitus in Iran: a systematic review and meta-analysis</article-title>. <source>Diabetes Metab Syndr</source> (<year>2017</year>) <volume>11</volume>(<issue>Suppl 1</issue>):<fpage>S99</fpage>&#x02013;<lpage>104</lpage>.<pub-id pub-id-type="doi">10.1016/j.dsx.2016.12.016</pub-id><pub-id pub-id-type="pmid">28017634</pub-id></mixed-citation></ref><ref id="B16"><label>16</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shapiro</surname><given-names>GD</given-names></name><name><surname>Arbuckle</surname><given-names>TE</given-names></name><name><surname>Ashley-Martin</surname><given-names>J</given-names></name><name><surname>Fraser</surname><given-names>WD</given-names></name><name><surname>Fisher</surname><given-names>M</given-names></name><name><surname>Bouchard</surname><given-names>MF</given-names></name><etal/></person-group>
<article-title>Associations between maternal triclosan concentrations in early pregnancy and gestational diabetes mellitus, impaired glucose tolerance, gestational weight gain and fetal markers of metabolic function</article-title>. <source>Environ Res</source> (<year>2017</year>) <volume>161</volume>:<fpage>554</fpage>&#x02013;<lpage>61</lpage>.<pub-id pub-id-type="doi">10.1016/j.envres.2017.12.001</pub-id></mixed-citation></ref><ref id="B17"><label>17</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cosson</surname><given-names>E</given-names></name><name><surname>Carbillon</surname><given-names>L</given-names></name><name><surname>Valensi</surname><given-names>P</given-names></name></person-group>
<article-title>High fasting plasma glucose during early pregnancy: a review about early gestational diabetes mellitus</article-title>. <source>J Diabetes Res</source> (<year>2017</year>) <volume>2017</volume>:<fpage>8921712.1</fpage><pub-id pub-id-type="doi">10.1155/2017/8921712</pub-id><pub-id pub-id-type="pmid">29181414</pub-id></mixed-citation></ref><ref id="B18"><label>18</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Seghieri</surname><given-names>G</given-names></name><name><surname>Anichini</surname><given-names>R</given-names></name><name><surname>De Bellis</surname><given-names>A</given-names></name><name><surname>Alviggi</surname><given-names>L</given-names></name><name><surname>Franconi</surname><given-names>F</given-names></name><name><surname>Breschi</surname><given-names>MC</given-names></name></person-group>. <article-title>Relationship between gestational diabetes mellitus and low maternal birth weight</article-title>. <source>Diabetes Care</source> (<year>2002</year>) <volume>25</volume>:<fpage>1761</fpage>&#x02013;<lpage>5</lpage>.<pub-id pub-id-type="doi">10.2337/diacare.25.10.1761</pub-id><pub-id pub-id-type="pmid">12351474</pub-id></mixed-citation></ref><ref id="B19"><label>19</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>LF</given-names></name><name><surname>Wang</surname><given-names>HJ</given-names></name><name><surname>Ao</surname><given-names>D</given-names></name><name><surname>Liu</surname><given-names>Z</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Yang</surname><given-names>HX</given-names></name></person-group>. <article-title>Influence of pre-pregnancy obesity on the development of macrosomia and large for gestational age in women with or without gestational diabetes mellitus in Chinese population</article-title>. <source>J Perinatol</source> (<year>2015</year>) <volume>35</volume>:<fpage>985</fpage>&#x02013;<lpage>90</lpage>.<pub-id pub-id-type="doi">10.1038/jp.2015.119</pub-id><pub-id pub-id-type="pmid">26401753</pub-id></mixed-citation></ref><ref id="B20"><label>20</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saraf-Bank</surname><given-names>S</given-names></name><name><surname>Tehrani</surname><given-names>H</given-names></name><name><surname>Haghighatdoost</surname><given-names>F</given-names></name><name><surname>Moosavian</surname><given-names>SP</given-names></name><name><surname>Azadbakht</surname><given-names>L</given-names></name></person-group>
<article-title>The acidity of early pregnancy diet and risk of gestational diabetes mellitus</article-title>. <source>Clin Nutr</source> (<year>2017</year>) <volume>S0261-5614</volume>(<issue>17</issue>):<fpage>31352</fpage>&#x02013;<lpage>3</lpage>.<pub-id pub-id-type="doi">10.1016/j.clnu.2017.09.020</pub-id></mixed-citation></ref><ref id="B21"><label>21</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bao</surname><given-names>W</given-names></name><name><surname>Song</surname><given-names>Y</given-names></name><name><surname>Bertrand</surname><given-names>KA</given-names></name><name><surname>Tobias</surname><given-names>DK</given-names></name><name><surname>Olsen</surname><given-names>SF</given-names></name><name><surname>Chavarro</surname><given-names>JE</given-names></name><etal/></person-group>
<article-title>Prepregnancy habitual intake of vitamin D from diet and supplements in relation to risk of gestational diabetes mellitus: a prospective cohort study</article-title>. <source>J Diabetes</source> (<year>2017</year>).<pub-id pub-id-type="doi">10.1111/1753-0407.12611</pub-id></mixed-citation></ref><ref id="B22"><label>22</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shepherd</surname><given-names>E</given-names></name><name><surname>Gomersall</surname><given-names>JC</given-names></name><name><surname>Tieu</surname><given-names>J</given-names></name><name><surname>Han</surname><given-names>S</given-names></name><name><surname>Crowther</surname><given-names>CA</given-names></name><name><surname>Middleton</surname><given-names>P</given-names></name></person-group>
<article-title>Combined diet and exercise interventions for preventing gestational diabetes mellitus</article-title>. <source>Cochrane Database Syst Rev</source> (<year>2017</year>) <volume>11</volume>:<fpage>CD010443.1</fpage><pub-id pub-id-type="doi">10.1002/14651858</pub-id><pub-id pub-id-type="pmid">29129039</pub-id></mixed-citation></ref><ref id="B23"><label>23</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Singh</surname><given-names>N</given-names></name><name><surname>Madhu</surname><given-names>M</given-names></name><name><surname>Vanamail</surname><given-names>P</given-names></name><name><surname>Malik</surname><given-names>N</given-names></name><name><surname>Kumar</surname><given-names>S</given-names></name></person-group>
<article-title>Efficacy of metformin in improving glycaemic control &#x00026; perinatal outcome in gestational diabetes mellitus: a non-randomized study</article-title>. <source>Indian J Med Res</source> (<year>2017</year>) <volume>145</volume>:<fpage>623</fpage>&#x02013;<lpage>8</lpage>.<pub-id pub-id-type="pmid">28948952</pub-id></mixed-citation></ref><ref id="B24"><label>24</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Foghsgaard</surname><given-names>S</given-names></name><name><surname>Vedtofte</surname><given-names>L</given-names></name><name><surname>Andreasen</surname><given-names>C</given-names></name><name><surname>Andersen</surname><given-names>ES</given-names></name><name><surname>Bahne</surname><given-names>E</given-names></name><name><surname>Bagger</surname><given-names>JI</given-names></name><etal/></person-group>
<article-title>Women with prior gestational diabetes mellitus and prediabetes are characterised by a decreased incretin effect</article-title>. <source>Diabetologia</source> (<year>2017</year>) <volume>60</volume>:<fpage>1344</fpage>&#x02013;<lpage>53</lpage>.<pub-id pub-id-type="doi">10.1007/s00125-017-4265-8</pub-id><pub-id pub-id-type="pmid">28364253</pub-id></mixed-citation></ref><ref id="B25"><label>25</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gante</surname><given-names>I</given-names></name><name><surname>Melo</surname><given-names>L</given-names></name><name><surname>Dores</surname><given-names>J</given-names></name><name><surname>Ruas</surname><given-names>L</given-names></name><name><surname>Almeida</surname><given-names>MDC</given-names></name></person-group>. <article-title>Metformin in gestational diabetes mellitus: predictors of poor response</article-title>. <source>Eur J Endocrinol</source> (<year>2018</year>) <volume>178</volume>:<fpage>131</fpage>&#x02013;<lpage>7</lpage>.<pub-id pub-id-type="doi">10.1530/EJE-17-0486</pub-id><pub-id pub-id-type="pmid">29070511</pub-id></mixed-citation></ref><ref id="B26"><label>26</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lebovitz</surname><given-names>HE</given-names></name></person-group>
<article-title>Incretin-based therapies: facing the realities of benefits versus side effects</article-title>. <source>Diabetes Technol Ther</source> (<year>2013</year>) <volume>15</volume>:<fpage>909</fpage>&#x02013;<lpage>13</lpage>.<pub-id pub-id-type="doi">10.1089/dia.2013.0274</pub-id><pub-id pub-id-type="pmid">24111860</pub-id></mixed-citation></ref><ref id="B27"><label>27</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>DT</given-names></name><name><surname>Lam</surname><given-names>SC</given-names></name><name><surname>Cheong</surname><given-names>KL</given-names></name><name><surname>Wei</surname><given-names>F</given-names></name><name><surname>Lin</surname><given-names>PC</given-names></name><name><surname>Long</surname><given-names>ZR</given-names></name><etal/></person-group>
<article-title>Simultaneous determination of molecular weights and contents of water-soluble polysaccharides and their fractions from <italic>Lycium barbarum</italic> collected in China</article-title>. <source>J Pharm Biomed Anal</source> (<year>2016</year>) <volume>129</volume>:<fpage>210</fpage>&#x02013;<lpage>8</lpage>.<pub-id pub-id-type="doi">10.1016/j.jpba.2016.07.005</pub-id><pub-id pub-id-type="pmid">27429371</pub-id></mixed-citation></ref><ref id="B28"><label>28</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Shi</surname><given-names>M</given-names></name><name><surname>Ma</surname><given-names>B</given-names></name><name><surname>Zheng</surname><given-names>Y</given-names></name><name><surname>Niu</surname><given-names>R</given-names></name><name><surname>Li</surname><given-names>K</given-names></name></person-group>. <article-title>Protective effects of fraction 4a of polysaccharides isolated from <italic>Lycium barbarum</italic> against KBrO3-induced renal damage in rats</article-title>. <source>Food Funct</source> (<year>2017</year>) <volume>8</volume>:<fpage>2566</fpage>&#x02013;<lpage>72</lpage>.<pub-id pub-id-type="doi">10.1039/c6fo01818a</pub-id><pub-id pub-id-type="pmid">28671197</pub-id></mixed-citation></ref><ref id="B29"><label>29</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>P</given-names></name><name><surname>Ma</surname><given-names>NT</given-names></name><name><surname>Chang</surname><given-names>RY</given-names></name><name><surname>Li</surname><given-names>YX</given-names></name><name><surname>Hao</surname><given-names>YJ</given-names></name><name><surname>Yang</surname><given-names>WL</given-names></name><etal/></person-group>
<article-title>Mechanism of <italic>Lycium barbarum</italic> polysaccharides on primary cultured rat hippocampal neurons</article-title>. <source>Cell Tissue Res</source> (<year>2017</year>).<pub-id pub-id-type="doi">10.1007/s00441-017-2648-2</pub-id><pub-id pub-id-type="pmid">28656471</pub-id></mixed-citation></ref><ref id="B30"><label>30</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>R</given-names></name><name><surname>Gao</surname><given-names>X</given-names></name><name><surname>Zhang</surname><given-names>T</given-names></name><name><surname>Li</surname><given-names>X</given-names></name></person-group>
<article-title>Effects of <italic>Lycium barbarum</italic>. polysaccharide on type 2 diabetes ellitus rats by regulating biological rhythms</article-title>. <source>Iran J Basic Med Sci</source> (<year>2016</year>) <volume>19</volume>:<fpage>1024</fpage>&#x02013;<lpage>30</lpage>.<pub-id pub-id-type="pmid">27803791</pub-id></mixed-citation></ref><ref id="B31"><label>31</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ouimet</surname><given-names>M</given-names></name><name><surname>Koster</surname><given-names>S</given-names></name><name><surname>Sakowski</surname><given-names>E</given-names></name><name><surname>Ramkhelawon</surname><given-names>B</given-names></name><name><surname>van Solingen</surname><given-names>C</given-names></name><name><surname>Oldebeken</surname><given-names>S</given-names></name><etal/></person-group>
<article-title><italic>Mycobacterium tuberculosis</italic> induces the miR-33 locus to reprogram autophagy and host lipid metabolism</article-title>. <source>Nat Immunol</source> (<year>2016</year>) <volume>17</volume>:<fpage>677</fpage>&#x02013;<lpage>86</lpage>.<pub-id pub-id-type="doi">10.1038/ni.3434</pub-id><pub-id pub-id-type="pmid">27089382</pub-id></mixed-citation></ref><ref id="B32"><label>32</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ono</surname><given-names>K</given-names></name><name><surname>Horie</surname><given-names>T</given-names></name><name><surname>Nishino</surname><given-names>T</given-names></name><name><surname>Baba</surname><given-names>O</given-names></name><name><surname>Kuwabara</surname><given-names>Y</given-names></name><name><surname>Yokode</surname><given-names>M</given-names></name><etal/></person-group>
<article-title>MicroRNA-33a/b in lipid metabolism&#x02014;novel &#x0201c;thrifty&#x0201d; models</article-title>. <source>Circ J</source> (<year>2015</year>) <volume>79</volume>:<fpage>278</fpage>&#x02013;<lpage>84</lpage>.<pub-id pub-id-type="doi">10.1253/circj.CJ-14-1252</pub-id><pub-id pub-id-type="pmid">25744742</pub-id></mixed-citation></ref><ref id="B33"><label>33</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>B</given-names></name><name><surname>Gillard</surname><given-names>BK</given-names></name><name><surname>Gotto</surname><given-names>AM</given-names><suffix>Jr</suffix></name><name><surname>Rosales</surname><given-names>C</given-names></name><name><surname>Pownall</surname><given-names>HJ</given-names></name></person-group>. <article-title>ABCA1-derived nascent high-density lipoprotein-apolipoprotein AI and lipids metabolically segregate</article-title>. <source>Arterioscler Thromb Vasc Biol</source> (<year>2017</year>) <volume>37</volume>:<fpage>2260</fpage>&#x02013;<lpage>70</lpage>.<pub-id pub-id-type="doi">10.1161/ATVBAHA.117.310290</pub-id><pub-id pub-id-type="pmid">29074589</pub-id></mixed-citation></ref><ref id="B34"><label>34</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ma</surname><given-names>W</given-names></name><name><surname>Ding</surname><given-names>H</given-names></name><name><surname>Gong</surname><given-names>X</given-names></name><name><surname>Liu</surname><given-names>Z</given-names></name><name><surname>Lin</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>Z</given-names></name><etal/></person-group>
<article-title>Methyl protodioscin increases ABCA1 expression and cholesterol efflux while inhibiting gene expressions for synthesis of cholesterol and triglycerides by suppressing SREBP transcription and microRNA 33a/b levels</article-title>. <source>Atherosclerosis</source> (<year>2015</year>) <volume>239</volume>:<fpage>566</fpage>&#x02013;<lpage>70</lpage>.<pub-id pub-id-type="doi">10.1016/j.atherosclerosis.2015.02.034</pub-id><pub-id pub-id-type="pmid">25733328</pub-id></mixed-citation></ref><ref id="B35"><label>35</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marvaki</surname><given-names>A</given-names></name><name><surname>Kolovou</surname><given-names>V</given-names></name><name><surname>Katsiki</surname><given-names>N</given-names></name><name><surname>Boutsikou</surname><given-names>M</given-names></name><name><surname>Kotanidou</surname><given-names>A</given-names></name><name><surname>Orfanos</surname><given-names>S</given-names></name><etal/></person-group>
<article-title>Impact of 3 common ABCA1 gene polymorphisms on optimal vs non-optimal lipid profile in Greek young nurses</article-title>. <source>Open Cardiovasc Med J</source> (<year>2014</year>) <volume>8</volume>:<fpage>83</fpage>&#x02013;<lpage>7</lpage>.<pub-id pub-id-type="doi">10.2174/1874192401408010083</pub-id><pub-id pub-id-type="pmid">25279016</pub-id></mixed-citation></ref><ref id="B36"><label>36</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>Y</given-names></name><name><surname>Ding</surname><given-names>D</given-names></name><name><surname>Huang</surname><given-names>Q</given-names></name><name><surname>Liu</surname><given-names>Q</given-names></name><name><surname>Lu</surname><given-names>H</given-names></name><name><surname>Lu</surname><given-names>Y</given-names></name><etal/></person-group>
<article-title>Downregulation of miR-192 causes hepatic steatosis and lipid accumulation by inducing SREBF1: Novel mechanism for bisphenol A-triggered non-alcoholic fatty liver disease</article-title>. <source>Biochim Biophys Acta</source> (<year>2017</year>) <volume>1862</volume>:<fpage>869</fpage>&#x02013;<lpage>82</lpage>.<pub-id pub-id-type="doi">10.1016/j.bbalip.2017.05.001</pub-id><pub-id pub-id-type="pmid">28483554</pub-id></mixed-citation></ref><ref id="B37"><label>37</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>H</given-names></name><name><surname>Fan</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>W</given-names></name><name><surname>Liu</surname><given-names>N</given-names></name><name><surname>Zhang</surname><given-names>H</given-names></name><name><surname>Zhu</surname><given-names>Z</given-names></name><etal/></person-group>
<article-title>Polysaccharides from <italic>Lycium barbarum</italic> leaves: isolation, characterization and splenocyte proliferation activity</article-title>. <source>Int J Biol Macromol</source> (<year>2012</year>) <volume>51</volume>:<fpage>417</fpage>&#x02013;<lpage>22</lpage>.<pub-id pub-id-type="doi">10.1016/j.ijbiomac.2012.05.025</pub-id><pub-id pub-id-type="pmid">22652219</pub-id></mixed-citation></ref><ref id="B38"><label>38</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alam</surname><given-names>N</given-names></name><name><surname>Gupta</surname><given-names>PC</given-names></name></person-group>. <article-title>Structure of a water-soluble polysaccharide from the seeds of <italic>Cassia angustifolia</italic></article-title>. <source>Planta Med</source> (<year>1986</year>) <volume>52</volume>(<issue>4</issue>):<fpage>308</fpage>&#x02013;<lpage>10</lpage>.<pub-id pub-id-type="doi">10.1055/s-2007-969161</pub-id><pub-id pub-id-type="pmid">17345316</pub-id></mixed-citation></ref><ref id="B39"><label>39</label><mixed-citation publication-type="journal"><collab>General Assembly of the World Medical Association</collab>. <article-title>World medical association declaration of Helsinki: ethical principles for medical research involving human subjects</article-title>. <source>J Am Coll Dent</source> (<year>2014</year>) <volume>81</volume>:<fpage>14</fpage>&#x02013;<lpage>8</lpage>.<pub-id pub-id-type="doi">10.1001/jama.2013.281053</pub-id><pub-id pub-id-type="pmid">25951678</pub-id></mixed-citation></ref><ref id="B40"><label>40</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schmidt</surname><given-names>MI</given-names></name><name><surname>Duncan</surname><given-names>BB</given-names></name><name><surname>Reichelt</surname><given-names>AJ</given-names></name><name><surname>Branchtein</surname><given-names>L</given-names></name><name><surname>Matos</surname><given-names>MC</given-names></name><name><surname>e Forti</surname><given-names>AC</given-names></name><etal/></person-group>
<article-title>Gestational diabetes mellitus diagnosed with a 2-h 75-g oral glucose tolerance test and adverse pregnancy outcomes</article-title>. <source>Diabetes Care</source> (<year>2001</year>) <volume>24</volume>:<fpage>1151</fpage>&#x02013;<lpage>5</lpage>.<pub-id pub-id-type="doi">10.2337/diacare.24.7.1151</pub-id><pub-id pub-id-type="pmid">11423494</pub-id></mixed-citation></ref><ref id="B41"><label>41</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Link</surname><given-names>M</given-names></name><name><surname>Schmid</surname><given-names>C</given-names></name><name><surname>Pleus</surname><given-names>S</given-names></name><name><surname>Baumstark</surname><given-names>A</given-names></name><name><surname>Rittmeyer</surname><given-names>D</given-names></name><name><surname>Haug</surname><given-names>C</given-names></name><etal/></person-group>
<article-title>System accuracy evaluation of four systems for self-monitoring of blood glucose following ISO 15197 using a glucose oxidase and a hexokinase-based comparison method</article-title>. <source>J Diabetes Sci Technol</source> (<year>2015</year>) <volume>9</volume>:<fpage>1041</fpage>&#x02013;<lpage>50</lpage>.<pub-id pub-id-type="doi">10.1177/1932296815580161</pub-id><pub-id pub-id-type="pmid">25872967</pub-id></mixed-citation></ref><ref id="B42"><label>42</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kern Pessoa</surname><given-names>VN</given-names></name><name><surname>Rodacki</surname><given-names>M</given-names></name><name><surname>Negrato</surname><given-names>CA</given-names></name><name><surname>Zajdenverg</surname><given-names>L</given-names></name></person-group>. <article-title>Changes in lipid profile after treatment of women with gestational diabetes mellitus</article-title>. <source>J Clin Lipidol</source> (<year>2016</year>) <volume>10</volume>:<fpage>350</fpage>&#x02013;<lpage>5</lpage>.<pub-id pub-id-type="doi">10.1016/j.jacl.2015.12.008</pub-id><pub-id pub-id-type="pmid">27055966</pub-id></mixed-citation></ref><ref id="B43"><label>43</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liang</surname><given-names>Z</given-names></name><name><surname>Wu</surname><given-names>Y</given-names></name><name><surname>Zhu</surname><given-names>X</given-names></name><name><surname>Fang</surname><given-names>Q</given-names></name><name><surname>Chen</surname><given-names>D</given-names></name></person-group>. <article-title>Insulin resistance and lipid profile during an oral glucose tolerance test in women with and without gestational diabetes mellitus</article-title>. <source>J Obstet Gynaecol</source> (<year>2016</year>) <volume>36</volume>:<fpage>337</fpage>&#x02013;<lpage>9</lpage>.<pub-id pub-id-type="doi">10.3109/01443615.2015.1060197</pub-id><pub-id pub-id-type="pmid">26466813</pub-id></mixed-citation></ref><ref id="B44"><label>44</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>Q</given-names></name><name><surname>Xing</surname><given-names>B</given-names></name></person-group>. <article-title>A phytosterol-enriched spread improves lipid profile and insulin resistance of women with gestational diabetes mellitus: a randomized, placebo-controlled double-blind clinical trial</article-title>. <source>Diabetes Technol Ther</source> (<year>2016</year>) <volume>18</volume>:<fpage>499</fpage>&#x02013;<lpage>504.1</lpage>.<pub-id pub-id-type="doi">10.1089/dia.2016.0103</pub-id><pub-id pub-id-type="pmid">27512827</pub-id></mixed-citation></ref><ref id="B45"><label>45</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>WB</given-names></name><name><surname>Hung</surname><given-names>DK</given-names></name><name><surname>Chang</surname><given-names>FW</given-names></name><name><surname>Ong</surname><given-names>ET</given-names></name><name><surname>Chen</surname><given-names>BH</given-names></name></person-group>. <article-title>Anti-inflammatory and anti-angiogenic effects of flavonoids isolated from <italic>Lycium barbarum</italic> Linnaeus on human umbilical vein endothelial cells</article-title>. <source>Food Funct</source> (<year>2012</year>) <volume>3</volume>:<fpage>1068</fpage>&#x02013;<lpage>81</lpage>.<pub-id pub-id-type="doi">10.1039/c2fo30051f</pub-id><pub-id pub-id-type="pmid">22751795</pub-id></mixed-citation></ref><ref id="B46"><label>46</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>He</surname><given-names>YL</given-names></name><name><surname>Ying</surname><given-names>Y</given-names></name><name><surname>Xu</surname><given-names>YL</given-names></name><name><surname>Su</surname><given-names>JF</given-names></name><name><surname>Luo</surname><given-names>H</given-names></name><name><surname>Wang</surname><given-names>HF</given-names></name></person-group>
<article-title>Effects of <italic>Lycium barbarum</italic> polysaccharide on tumor microenvironment T-lymphocyte subsets and dendritic cells in H22-bearing mice</article-title>. <source>Zhong Xi Yi Jie He Xue Bao</source> (<year>2005</year>) <volume>3</volume>:<fpage>374</fpage>&#x02013;<lpage>7</lpage>.<pub-id pub-id-type="doi">10.3736/jcim20050511</pub-id><pub-id pub-id-type="pmid">16159572</pub-id></mixed-citation></ref><ref id="B47"><label>47</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Souza Zanchet</surname><given-names>MZ</given-names></name><name><surname>Nardi</surname><given-names>GM</given-names></name><name><surname>de Oliveira Souza Bratti</surname><given-names>L</given-names></name><name><surname>Filippin-Monteiro</surname><given-names>FB</given-names></name><name><surname>Locatelli</surname><given-names>C</given-names></name></person-group>. <article-title><italic>Lycium barbarum</italic> reduces abdominal fat and improves lipid profile and antioxidant status in patients with metabolic syndrome</article-title>. <source>Oxid Med Cell Longev</source> (<year>2017</year>) <volume>2017</volume>:<fpage>9763210.1</fpage>.<pub-id pub-id-type="doi">10.1155/2017/9763210</pub-id><pub-id pub-id-type="pmid">28685012</pub-id></mixed-citation></ref><ref id="B48"><label>48</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alsaggaf</surname><given-names>MS</given-names></name><name><surname>Moussa</surname><given-names>SH</given-names></name><name><surname>Elguindy</surname><given-names>NM</given-names></name><name><surname>Tayel</surname><given-names>AA</given-names></name></person-group>. <article-title>Fungal chitosan and <italic>Lycium barbarum</italic> extract as anti-listeria and quality preservatives in minced catfish</article-title>. <source>Int J Biol Macromol</source> (<year>2017</year>) <volume>104</volume>:<fpage>854</fpage>&#x02013;<lpage>61</lpage>.<pub-id pub-id-type="doi">10.1016/j.ijbiomac.2017.06.097</pub-id><pub-id pub-id-type="pmid">28655659</pub-id></mixed-citation></ref><ref id="B49"><label>49</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cheng</surname><given-names>L</given-names></name><name><surname>Zhu</surname><given-names>Y</given-names></name><name><surname>Han</surname><given-names>H</given-names></name><name><surname>Zhang</surname><given-names>Q</given-names></name><name><surname>Cui</surname><given-names>K</given-names></name><name><surname>Shen</surname><given-names>H</given-names></name><etal/></person-group>
<article-title>MicroRNA-148a deficiency promotes hepatic lipid metabolism and hepatocarcinogenesis in mice</article-title>. <source>Cell Death Dis</source> (<year>2017</year>) <volume>8</volume>:<fpage>e2916.1</fpage>.<pub-id pub-id-type="doi">10.1038/cddis.2017.309</pub-id><pub-id pub-id-type="pmid">28703810</pub-id></mixed-citation></ref><ref id="B50"><label>50</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Su</surname><given-names>D</given-names></name><name><surname>Zhang</surname><given-names>R</given-names></name><name><surname>Hou</surname><given-names>F</given-names></name><name><surname>Chi</surname><given-names>J</given-names></name><name><surname>Huang</surname><given-names>F</given-names></name><name><surname>Yan</surname><given-names>S</given-names></name><etal/></person-group>
<article-title>Lychee pulp phenolics ameliorate hepatic lipid accumulation by reducing miR-33 and miR-122 expression in mice fed a high-fat diet</article-title>. <source>Food Funct</source> (<year>2017</year>) <volume>8</volume>:<fpage>808</fpage>&#x02013;<lpage>15</lpage>.<pub-id pub-id-type="doi">10.1039/c6fo01507g</pub-id><pub-id pub-id-type="pmid">28121324</pub-id></mixed-citation></ref><ref id="B51"><label>51</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rayner</surname><given-names>KJ</given-names></name><name><surname>Su&#x000e1;rez</surname><given-names>Y</given-names></name><name><surname>D&#x000e1;valos</surname><given-names>A</given-names></name><name><surname>Parathath</surname><given-names>S</given-names></name><name><surname>Fitzgerald</surname><given-names>ML</given-names></name><name><surname>Tamehiro</surname><given-names>N</given-names></name><etal/></person-group>
<article-title>MiR-33 contributes to the regulation of cholesterol homeostasis</article-title>. <source>Science</source> (<year>2010</year>) <volume>328</volume>:<fpage>1570</fpage>&#x02013;<lpage>3</lpage>.<pub-id pub-id-type="doi">10.1126/science.1189862</pub-id><pub-id pub-id-type="pmid">20466885</pub-id></mixed-citation></ref><ref id="B52"><label>52</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hu</surname><given-names>CK</given-names></name><name><surname>Lee</surname><given-names>YJ</given-names></name><name><surname>Colitz</surname><given-names>CM</given-names></name><name><surname>Chang</surname><given-names>CJ</given-names></name><name><surname>Lin</surname><given-names>CT</given-names></name></person-group>. <article-title>The protective effects of <italic>Lycium barbarum</italic> and <italic>Chrysanthemum morifolum</italic> on diabetic retinopathies in rats</article-title>. <source>Vet Ophthalmol</source> (<year>2012</year>) <volume>15</volume>:<fpage>65</fpage>&#x02013;<lpage>71</lpage>.<pub-id pub-id-type="doi">10.1111/j.1463-5224.2012.01018.x</pub-id><pub-id pub-id-type="pmid">22487267</pub-id></mixed-citation></ref><ref id="B53"><label>53</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>R</given-names></name><name><surname>Li</surname><given-names>Q</given-names></name><name><surname>Xiao</surname><given-names>B</given-names></name></person-group>. <article-title>Effect of <italic>Lycium barbarum</italic> polysaccharide on the improvement of insulin resistance in NIDDM rats</article-title>. <source>Yakugaku Zasshi</source> (<year>2005</year>) <volume>125</volume>:<fpage>981</fpage>&#x02013;<lpage>8</lpage>.<pub-id pub-id-type="doi">10.1248/yakushi.125.981</pub-id><pub-id pub-id-type="pmid">16327243</pub-id></mixed-citation></ref><ref id="B54"><label>54</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>R</given-names></name><name><surname>Jin</surname><given-names>R</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Han</surname><given-names>F-M</given-names></name></person-group>
<article-title>Hypoglycemic and hypolipidemic effects of <italic>Lycium barbarum</italic> polysaccharide in diabetic rats</article-title>. <source>Chin Herb Med</source> (<year>2015</year>) <volume>7</volume>:<fpage>310</fpage>&#x02013;<lpage>5</lpage>.<pub-id pub-id-type="doi">10.1016/S1674-6384(15)60057-0</pub-id></mixed-citation></ref><ref id="B55"><label>55</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>YJ</given-names></name><name><surname>Ku</surname><given-names>S-Y</given-names></name><name><surname>Rosenwaks</surname><given-names>Z</given-names></name><name><surname>Liu</surname><given-names>HC</given-names></name><name><surname>Chi</surname><given-names>SW</given-names></name><name><surname>Kang</surname><given-names>JS</given-names></name><etal/></person-group>
<article-title>MicroRNA expression profiles are altered by gonadotropins and vitamin C status during in vitro follicular growth</article-title>. <source>Reprod Sci</source> (<year>2010</year>) <volume>17</volume>(<issue>12</issue>):<fpage>1081</fpage>&#x02013;<lpage>9</lpage>.<pub-id pub-id-type="doi">10.1177/1933719110377663</pub-id><pub-id pub-id-type="pmid">20861395</pub-id></mixed-citation></ref><ref id="B56"><label>56</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>H</given-names></name><name><surname>Chen</surname><given-names>JX</given-names></name><name><surname>Yang</surname><given-names>CS</given-names></name><name><surname>Yang</surname><given-names>MQ</given-names></name><name><surname>Deng</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name></person-group>. <article-title>Gene regulation mediated by microRNAs in response to green tea polyphenol EGCG in mouse lung cancer</article-title>. <source>BMC Genomics</source> (<year>2014</year>) <volume>15</volume>(<issue>Suppl 11</issue>):<fpage>S3.1</fpage>.<pub-id pub-id-type="doi">10.1186/1471-2164-15-S11-S3</pub-id><pub-id pub-id-type="pmid">25559244</pub-id></mixed-citation></ref><ref id="B57"><label>57</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tomosugi</surname><given-names>M</given-names></name><name><surname>Sowa</surname><given-names>Y</given-names></name><name><surname>Yasuda</surname><given-names>S</given-names></name><name><surname>Tanaka</surname><given-names>R</given-names></name><name><surname>te Riele</surname><given-names>H</given-names></name><name><surname>Ikawa</surname><given-names>H</given-names></name><etal/></person-group>
<article-title>Retinoblastoma gene-independent G1 phase arrest by flavone, phosphatidylinositol 3-kinase inhibitor, and histone deacetylase inhibitor</article-title>. <source>Cancer Sci</source> (<year>2012</year>) <volume>103</volume>:<fpage>2139</fpage>&#x02013;<lpage>43</lpage>.<pub-id pub-id-type="doi">10.1111/cas.12012</pub-id><pub-id pub-id-type="pmid">22957647</pub-id></mixed-citation></ref><ref id="B58"><label>58</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>A</given-names></name><name><surname>Shuai</surname><given-names>X</given-names></name><name><surname>Jia</surname><given-names>Z</given-names></name><name><surname>Li</surname><given-names>H</given-names></name><name><surname>Liang</surname><given-names>X</given-names></name><name><surname>Su</surname><given-names>D</given-names></name><etal/></person-group>
<article-title><italic>Ganoderma lucidum</italic> polysaccharide extract inhibits hepatocellular carcinoma growth by downregulating regulatory T cells accumulation and function by inducing microRNA-125b</article-title>. <source>J Transl Med</source> (<year>2015</year>) <volume>13</volume>:<fpage>100.1</fpage>.<pub-id pub-id-type="doi">10.1186/s12967-015-0465-5</pub-id><pub-id pub-id-type="pmid">25889022</pub-id></mixed-citation></ref><ref id="B59"><label>59</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grarup</surname><given-names>N</given-names></name><name><surname>Stender-Petersen</surname><given-names>KL</given-names></name><name><surname>Andersson</surname><given-names>EA</given-names></name><name><surname>J&#x000f8;rgensen</surname><given-names>T</given-names></name><name><surname>Borch-Johnsen</surname><given-names>K</given-names></name><name><surname>Sandbaek</surname><given-names>A</given-names></name><etal/></person-group>
<article-title>Association of variants in the sterol regulatory element-binding factor 1 (SREBF1) gene with type 2 diabetes, glycemia, and insulin resistance: a study of 15,734 Danish subjects</article-title>. <source>Diabetes</source> (<year>2008</year>) <volume>57</volume>:<fpage>1136</fpage>&#x02013;<lpage>42</lpage>.<pub-id pub-id-type="doi">10.2337/db07-1534</pub-id><pub-id pub-id-type="pmid">18192539</pub-id></mixed-citation></ref><ref id="B60"><label>60</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>JX</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>PQ</given-names></name><name><surname>Xie</surname><given-names>XD</given-names></name><name><surname>Guo</surname><given-names>Q</given-names></name><name><surname>Tian</surname><given-names>LM</given-names></name><etal/></person-group>
<article-title>Association of sterol regulatory element-binding protein-1c gene polymorphism with type 2 diabetes mellitus, insulin resistance and blood lipid levels in Chinese population</article-title>. <source>Diabetes Res Clin Pract</source> (<year>2008</year>) <volume>82</volume>:<fpage>42</fpage>&#x02013;<lpage>7</lpage>.<pub-id pub-id-type="doi">10.1016/j.diabres.2008.06.017</pub-id><pub-id pub-id-type="pmid">18692268</pub-id></mixed-citation></ref><ref id="B61"><label>61</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Seo</surname><given-names>JB</given-names></name><name><surname>Noh</surname><given-names>MJ</given-names></name><name><surname>Yoo</surname><given-names>EJ</given-names></name><name><surname>Park</surname><given-names>SY</given-names></name><name><surname>Park</surname><given-names>J</given-names></name><name><surname>Lee</surname><given-names>IK</given-names></name><etal/></person-group>
<article-title>Functional characterization of the human resistin promoter with adipocyte determination- and differentiation-dependent factor 1/sterol regulatory element binding protein 1c and CCAAT enhancer binding protein-alpha</article-title>. <source>Mol Endocrinol</source> (<year>2003</year>) <volume>17</volume>:<fpage>1522</fpage>&#x02013;<lpage>33</lpage>.<pub-id pub-id-type="doi">10.1210/me.2003-0028</pub-id><pub-id pub-id-type="pmid">12730330</pub-id></mixed-citation></ref><ref id="B62"><label>62</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sassek</surname><given-names>M</given-names></name><name><surname>Pruszynska-Oszmalek</surname><given-names>E</given-names></name><name><surname>Ko&#x00142;odziejski</surname><given-names>PA</given-names></name><name><surname>Szczepankiewicz</surname><given-names>D</given-names></name><name><surname>Kaczmarek</surname><given-names>P</given-names></name><name><surname>Wieloch</surname><given-names>M</given-names></name><etal/></person-group>
<article-title>Resistin is produced by rat pancreatic islets and regulates insulin and glucagon in vitro secretion</article-title>. <source>Islets</source> (<year>2016</year>) <volume>8</volume>:<fpage>177</fpage>&#x02013;<lpage>85</lpage>.<pub-id pub-id-type="doi">10.1080/19382014.2016.1251538</pub-id><pub-id pub-id-type="pmid">27797297</pub-id></mixed-citation></ref><ref id="B63"><label>63</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>HF</given-names></name><name><surname>Luo</surname><given-names>J</given-names></name><name><surname>Zhao</surname><given-names>WS</given-names></name><name><surname>Yang</surname><given-names>YC</given-names></name><name><surname>Tian</surname><given-names>HB</given-names></name><name><surname>Shi</surname><given-names>HB</given-names></name><etal/></person-group>
<article-title>Overexpression of SREBP1 (sterol regulatory element binding protein 1) promotes de novo fatty acid synthesis and triacylglycerol accumulation in goat mammary epithelial cells</article-title>. <source>J Dairy Sci</source> (<year>2016</year>) <volume>99</volume>:<fpage>783</fpage>&#x02013;<lpage>95</lpage>.<pub-id pub-id-type="doi">10.3168/jds.2015-9736</pub-id><pub-id pub-id-type="pmid">26601584</pub-id></mixed-citation></ref><ref id="B64"><label>64</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Im</surname><given-names>SS</given-names></name><name><surname>Hammond</surname><given-names>LE</given-names></name><name><surname>Yousef</surname><given-names>L</given-names></name><name><surname>Nugas-Selby</surname><given-names>C</given-names></name><name><surname>Shin</surname><given-names>DJ</given-names></name><name><surname>Seo</surname><given-names>YK</given-names></name><etal/></person-group>
<article-title>Sterol regulatory element binding protein 1a regulates hepatic fatty acid partitioning by activating acetyl coenzyme A carboxylase 2</article-title>. <source>Mol Cell Biol</source> (<year>2009</year>) <volume>29</volume>:<fpage>4864</fpage>&#x02013;<lpage>72</lpage>.<pub-id pub-id-type="doi">10.1128/MCB.00553-09</pub-id><pub-id pub-id-type="pmid">19564420</pub-id></mixed-citation></ref><ref id="B65"><label>65</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Desgagn&#x000e9;</surname><given-names>V</given-names></name><name><surname>Gu&#x000e9;rin</surname><given-names>R</given-names></name><name><surname>Guay</surname><given-names>SP</given-names></name><name><surname>Corbin</surname><given-names>F</given-names></name><name><surname>Couture</surname><given-names>P</given-names></name><name><surname>Lamarche</surname><given-names>B</given-names></name><etal/></person-group>
<article-title>Changes in high-density lipoprotein-carried miRNA contribution to the plasmatic pool after consumption of dietary trans fat in healthy men</article-title>. <source>Epigenomics</source> (<year>2017</year>) <volume>9</volume>:<fpage>669</fpage>&#x02013;<lpage>88</lpage>.<pub-id pub-id-type="doi">10.2217/epi-2016-0177</pub-id><pub-id pub-id-type="pmid">28470118</pub-id></mixed-citation></ref><ref id="B66"><label>66</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Forbes</surname><given-names>S</given-names></name><name><surname>Godsland</surname><given-names>IF</given-names></name><name><surname>Taylor-Robinson</surname><given-names>SD</given-names></name><name><surname>Bell</surname><given-names>JD</given-names></name><name><surname>Thomas</surname><given-names>EL</given-names></name><name><surname>Patel</surname><given-names>N</given-names></name><etal/></person-group>
<article-title>A history of previous gestational diabetes mellitus is associated with adverse changes in insulin secretion and VLDL metabolism independently of increased intrahepatocellular lipid</article-title>. <source>Diabetologia</source> (<year>2013</year>) <volume>56</volume>:<fpage>2021</fpage>&#x02013;<lpage>33</lpage>.<pub-id pub-id-type="doi">10.1007/s00125-013-2956-3</pub-id><pub-id pub-id-type="pmid">23760677</pub-id></mixed-citation></ref><ref id="B67"><label>67</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ye</surname><given-names>Q</given-names></name><name><surname>Zhao</surname><given-names>X</given-names></name><name><surname>Xu</surname><given-names>K</given-names></name><name><surname>Li</surname><given-names>Q</given-names></name><name><surname>Cheng</surname><given-names>J</given-names></name><name><surname>Gao</surname><given-names>Y</given-names></name><etal/></person-group>
<article-title>Polymorphisms in lipid metabolism related miRNA binding sites and risk of metabolic syndrome</article-title>. <source>Gene</source> (<year>2013</year>) <volume>528</volume>:<fpage>132</fpage>&#x02013;<lpage>8</lpage>.<pub-id pub-id-type="doi">10.1016/j.gene.2013.07.036</pub-id><pub-id pub-id-type="pmid">23911300</pub-id></mixed-citation></ref><ref id="B68"><label>68</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peng</surname><given-names>XP</given-names></name><name><surname>Huang</surname><given-names>L</given-names></name><name><surname>Liu</surname><given-names>ZH</given-names></name></person-group>. <article-title>miRNA-133a attenuates lipid accumulation via TR4-CD36 pathway in macrophages</article-title>. <source>Biochimie</source> (<year>2016</year>) <volume>127</volume>:<fpage>79</fpage>&#x02013;<lpage>85.1</lpage>.<pub-id pub-id-type="doi">10.1016/j.biochi.2016.04.012</pub-id><pub-id pub-id-type="pmid">27109382</pub-id></mixed-citation></ref><ref id="B69"><label>69</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goedeke</surname><given-names>L</given-names></name><name><surname>Wagschal</surname><given-names>A</given-names></name><name><surname>Fernandez-Hernando</surname><given-names>C</given-names></name><name><surname>Naar</surname><given-names>AM</given-names></name></person-group>. <article-title>miRNA regulation of LDL-cholesterol metabolism</article-title>. <source>Biochim Biophys Acta</source> (<year>2016</year>) <volume>1861</volume>:<fpage>2047</fpage>&#x02013;<lpage>52</lpage>.<pub-id pub-id-type="doi">10.1016/j.bbalip.2016.03.007</pub-id><pub-id pub-id-type="pmid">26968099</pub-id></mixed-citation></ref><ref id="B70"><label>70</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liang</surname><given-names>C</given-names></name><name><surname>Xiong</surname><given-names>K</given-names></name><name><surname>Szulwach</surname><given-names>KE</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Peng</surname><given-names>J</given-names></name><etal/></person-group>
<article-title>Sjogren syndrome antigen B (SSB)/La promotes global microRNA expression by binding microRNA precursors through stem-loop recognition</article-title>. <source>J Biol Chem</source> (<year>2013</year>) <volume>288</volume>:<fpage>723</fpage>&#x02013;<lpage>36</lpage>.<pub-id pub-id-type="doi">10.1074/jbc.M112.401323</pub-id><pub-id pub-id-type="pmid">23129761</pub-id></mixed-citation></ref><ref id="B71"><label>71</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>H</given-names></name><name><surname>Kohane</surname><given-names>IS</given-names></name></person-group>. <article-title>Tissue and process specific microRNA-mRNA co-expression in mammalian development and malignancy</article-title>. <source>PLoS One</source> (<year>2009</year>) <volume>4</volume>:<fpage>e5436.1</fpage>.<pub-id pub-id-type="doi">10.1371/journal.pone.0005436</pub-id><pub-id pub-id-type="pmid">19415117</pub-id></mixed-citation></ref><ref id="B72"><label>72</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ghasemi</surname><given-names>A</given-names></name><name><surname>Fallah</surname><given-names>S</given-names></name></person-group>. <article-title>Epigenetic modification of MicroRNA-205 and its association with glioblastoma multiform</article-title>. <source>Clin Lab</source> (<year>2017</year>) <volume>63</volume>:<fpage>1079</fpage>&#x02013;<lpage>88</lpage>.<pub-id pub-id-type="doi">10.7754/Clin.Lab.2017.161123</pub-id><pub-id pub-id-type="pmid">28792704</pub-id></mixed-citation></ref><ref id="B73"><label>73</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bahar</surname><given-names>B</given-names></name><name><surname>O&#x02019;Doherty</surname><given-names>JV</given-names></name><name><surname>O&#x02019;Doherty</surname><given-names>AM</given-names></name><name><surname>Sweeney</surname><given-names>T</given-names></name></person-group>. <article-title>Chito-oligosaccharide inhibits the de-methylation of a &#x02019;CpG&#x02019; island within the leptin (LEP) promoter during adipogenesis of 3T3-L1 cells</article-title>. <source>PLoS One</source> (<year>2013</year>) <volume>8</volume>:<fpage>e60011.1</fpage>.<pub-id pub-id-type="doi">10.1371/journal.pone.0060011</pub-id><pub-id pub-id-type="pmid">23544120</pub-id></mixed-citation></ref><ref id="B74"><label>74</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pennington</surname><given-names>KA</given-names></name><name><surname>Schlitt</surname><given-names>JM</given-names></name><name><surname>Schulz</surname><given-names>LC</given-names></name></person-group>
<article-title>Isolation of primary mouse trophoblast cells and trophoblast invasion assay</article-title>. <source>J Vis Exp</source> (<year>2012</year>) (<issue>59</issue>):<fpage>e3202</fpage><pub-id pub-id-type="doi">10.3791/3202</pub-id><pub-id pub-id-type="pmid">22257865</pub-id></mixed-citation></ref><ref id="B75"><label>75</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Hadden</surname><given-names>C</given-names></name><name><surname>Singh</surname><given-names>P</given-names></name><name><surname>Mercado</surname><given-names>CP</given-names></name><name><surname>Murphy</surname><given-names>P</given-names></name><name><surname>Dajani</surname><given-names>NK</given-names></name><etal/></person-group>
<article-title>GDM-associated insulin deficiency hinders the dissociation of SERT from ERp44 and down-regulates placental 5-HT uptake</article-title>. <source>Proc Natl Acad Sci U S A</source> (<year>2014</year>) <volume>111</volume>:<fpage>E5697</fpage>&#x02013;<lpage>705</lpage>.<pub-id pub-id-type="doi">10.1073/pnas.1416675112</pub-id><pub-id pub-id-type="pmid">25512553</pub-id></mixed-citation></ref><ref id="B76"><label>76</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blazevic</surname><given-names>S</given-names></name><name><surname>Horvaticek</surname><given-names>M</given-names></name><name><surname>Kesic</surname><given-names>M</given-names></name><name><surname>Zill</surname><given-names>P</given-names></name><name><surname>Hranilovic</surname><given-names>D</given-names></name><name><surname>Ivanisevic</surname><given-names>M</given-names></name><etal/></person-group>
<article-title>Epigenetic adaptation of the placental serotonin transporter gene (SLC6A4) to gestational diabetes mellitus</article-title>. <source>PLoS One</source> (<year>2017</year>) <volume>12</volume>:<fpage>e0179934.1</fpage>.<pub-id pub-id-type="doi">10.1371/journal.pone.0179934</pub-id><pub-id pub-id-type="pmid">28650965</pub-id></mixed-citation></ref><ref id="B77"><label>77</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Cooper</surname><given-names>A</given-names></name><name><surname>Odibo</surname><given-names>IN</given-names></name><name><surname>Ahmed</surname><given-names>A</given-names></name><name><surname>Murphy</surname><given-names>P</given-names></name><name><surname>Koonce</surname><given-names>R</given-names></name><etal/></person-group>
<article-title>Discrepancy in insulin regulation between gestational diabetes mellitus (GDM) platelets and placenta</article-title>. <source>J Biol Chem</source> (<year>2016</year>) <volume>291</volume>:<fpage>9657</fpage>&#x02013;<lpage>65</lpage>.<pub-id pub-id-type="doi">10.1074/jbc.M116.713693</pub-id><pub-id pub-id-type="pmid">26921319</pub-id></mixed-citation></ref></ref-list></back></article>